Previous Article in Journal
Role of Reactive Oxygen Species in Collagen-Induced Platelet Activation and the Protective Effects of Antioxidants
Previous Article in Special Issue
Various Cellular Components and Its Signaling Cascades Through the Involvement of Signaling Messengers in Keratinocyte Differentiation
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Synthetic and Natural Agents Targeting Advanced Glycation End-Products for Skin Anti-Aging: A Comprehensive Review of Experimental and Clinical Studies

1
Department of Biomedical Science, The Graduate School, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu 41944, Republic of Korea
2
BK21 Plus KNU Biomedical Convergence Program, Kyungpook National University, Daegu 41944, Republic of Korea
3
Department of Dermatology, Kyungpook National University Hospital, Daegu 41944, Republic of Korea
4
Bio-Medical Research Institute, Kyungpook National University Hospital, Daegu 41944, Republic of Korea
5
Department of Dermatology, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea
6
Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea
7
Cell and Matrix Research Institute, Kyungpook National University, Daegu 41944, Republic of Korea
*
Author to whom correspondence should be addressed.
Antioxidants 2025, 14(4), 498; https://doi.org/10.3390/antiox14040498 (registering DOI)
Submission received: 19 March 2025 / Revised: 17 April 2025 / Accepted: 18 April 2025 / Published: 20 April 2025
(This article belongs to the Special Issue Antioxidants for Skin Health)

Abstract

:
Advanced glycation end-products (AGEs) cause blood vessel damage and induce diabetic complications in various organs, such as the eyes, kidneys, nerves, and skin. As glycation stress causes aesthetic, physical, and functional changes in the skin, glycation-targeting skin anti-aging strategies are attracting attention in cosmetology and dermatology. The primary goal of this review is to understand the significance of glycation-induced skin aging and to examine the therapeutic potential of glycation-targeting strategies. This study covers experimental and clinical studies exploring various interventions to attenuate glycation-induced skin aging. Glycation stress decreases the viability of cells in culture media, the cell-mediated contraction of collagen lattices in reconstructed skin models, and the expression of fibrillin-1 at the dermo-epidermal junction in the skin explants. It also increases cross-links in tail tendon collagen in animals, prolonging its breakdown time. However, these changes are attenuated by several synthetic and natural agents. Animal and clinical studies have shown that dietary or topical administration of agents with antiglycation or antioxidant activity can attenuate changes in AGE levels (measured by skin autofluorescence) and skin aging parameters (e.g., skin color, wrinkles, elasticity, hydration, dermal density) induced by chronological aging, diabetes, high-carbohydrate diets, ultraviolet radiation, or oxidative stress. Therefore, the accumulating experimental and clinical evidence supports that dietary supplements or topical formulations containing one or more synthetic and natural antiglycation agents may help mitigate skin aging induced by AGEs.

1. Introduction

When we talk about the aging of the body, skin aging is often the first thing that comes to mind because it is easily visible to the naked eye [1,2]. Among the various changes that accompany skin aging, the aesthetic changes of skin appearance, such as wrinkles, sagging, color, and gloss, are of particular interest in cosmetology, and the physical and functional changes in skin barrier integrity, immune response, wound healing, and other physiological aspects are of significant importance in dermatology [3,4]. Skin aging is theoretically divided into intrinsic and extrinsic types based on the origin of the causal factors, but in reality, the boundaries are ambiguous due to many overlapping factors [5,6]. Innate genetic traits and chronological aging are included in intrinsic skin aging factors [5], while environmental factors, such as ultraviolet (UV) rays, air pollution, and dry climate, are included in extrinsic skin aging factors [7,8,9]. On the other hand, smoking, drinking alcohol, drug use, and dietary habits may be considered mixed skin aging factors because these behaviors introduce external substances into the body, which then undergo chemical changes due to internal metabolism or environmental influences [10,11]. Intrinsic, extrinsic, and mixed skin aging factors can all have negative effects on the appearance and function of the skin in general.
Dietary carbohydrates are digested in the body to produce monosaccharides, such as glucose, fructose, and galactose. These monosaccharides are metabolized into small molecules through the glycolytic pathway and the citric acid cycle, generating NADH and FADH2, which are oxidized in the electron transport chain of the mitochondria for ATP synthesis [12]. Thus, under normal physiological conditions, carbohydrates function as essential nutrients that provide metabolites and energy required for cell survival and function. However, under pathological conditions (e.g., persistent hyperglycemia due to diabetes), they participate in non-enzymatic condensation reactions with proteins, lipids, and nucleic acids, forming advanced glycation end-products (AGEs) [13,14]. Glycation reactions also increase according to chronological age, inactive lifestyle, the consumption of high-carbohydrate diets, and exposure to UV rays [15,16,17,18]. AGEs are considered to be one of the representative mixed skin aging factors that combine external sources, intrinsic pathological alterations, and environmental exposures [19,20].
Reducing sugars, such as aldoses (e.g., glucose) and ketoses (e.g., fructose), can form Schiff bases in which their carbonyl groups are linked to free amine groups of various substrates, such as proteins, lipids, and nucleic acids, via the Maillard pathway or the polyol pathway [21,22]. These adducts then form early glycation products, such as Amadori products (e.g., glucose-derived AGEs) and Heyns products (e.g., fructose-derived AGEs), through intramolecular rearrangements. These early glycation products undergo oxidative degradation, generating various forms of reactive aldehydes (e.g., glyceraldehyde, glycolaldehyde), dialdehydes (e.g., diacetyl, glyoxal, methylglyoxal), diketones (e.g., 1-deoxyglucosone, 3-deoxyglucosone), etc., which participate in the formation of various types of AGEs [23,24,25,26]. Glycation products include the early glycation products (not included in AGEs), such as fructosamine and furosine; the intermediate glycation products, such as Nε-(carboxymethyl)lysine (CML), Nω-(carboxymethyl)arginine (CMA), and Nε-(carboxyethyl)lysine (CEL); and the late glycation products, such as Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine [also called “methylglyoxal-derived hydroimidazolone 1 (MG-H1)”], argpyrimidine, pentosidine, and glucosepane. The receptor for advanced glycation end-products (RAGE) is highly expressed in the skin [27] and mediates several cell-signaling pathways involved in inflammation, fibrosis, melanin synthesis, etc. [28,29]. AGEs stimulate the production of reactive oxygen species (ROS) via NAD(P)H oxidase- or mitochondrion-dependent mechanisms, worsening diabetes and diabetic complications [14,30,31,32]. Glycation inhibitors, such as aminoguanidine (AGD), and antioxidants, such as N-acetylcysteine and glutathione, have been shown to attenuate the toxic effects of AGEs [33,34,35]. Different types of breakers of the preformed AGEs have been studied as a therapeutic approach [36,37,38,39].
There are previous review papers that provide an overview of the molecular mechanisms, pathogenesis, and inhibition strategies of glycation reactions [15] and a comprehensive discussion of the therapeutic potential of various natural compounds that inhibit the formation of AGEs [40]. There are also review papers that focus on the skin, examining the formation and effects of AGEs in the skin, methods for measuring skin AGE levels, and strategies to reduce skin glycation stress [19,41]. Despite the existence of such excellent review papers, there is a lack of a comprehensive review of the experimental and clinical evidence supporting or opposing the therapeutic potential of various interventions on glycation-induced skin aging.
The goal of this review is to understand the significance of glycation-induced skin aging and to explore treatment strategies for the mitigation of glycation-induced skin aging. We comprehensively examine the experimental and clinical studies on the relationship between glycation and skin aging and the various interventions with synthetic and natural agents. This review limits its scope to skin aging induced by glycation, excluding other specific skin diseases. It covers studies at various levels, namely, in vitro studies undertaken using proteins, cells, and reconstructed skin models; ex vivo studies using live skin explants; in vivo studies using animals; and clinical studies involving human subjects. We hope that this comprehensive review will help recognize the significance of skin aging induced by AGEs and develop treatment strategies against glycation-induced skin aging.

2. Methods

We searched the PubMed (https://pubmed.ncbi.nlm.nih.gov/, accessed on 1 March 2025), Web of Science (https://www.webofscience.com/, accessed on 1 March 2025), and Google Scholar (https://scholar.google.com/, accessed on 1 March 2025) databases for experimental and clinical studies on the topic of this narrative review using various keywords, such as ‘advanced glycation end-products’, ‘skin aging’, ‘antioxidants’, ‘aminoguanidine’, ‘in vitro’, ‘ex vivo’, ‘in vivo’, ‘animal’, ‘mice’, ‘rats’, ‘chicks’, ‘clinical’, ‘synthetic’, and ‘natural’, using Boolean search commands, such as ‘AND’ and ‘OR’. The selected articles were cited and discussed in the appropriate chapter(s) or section(s) according to the level of studies, such as in vitro, ex vivo, in vivo (animal), and clinical studies.

3. Significance of Glycation-Induced Skin Aging

3.1. Experimental Evidence

As summarized in Table 1, increases in AGE levels in blood, skin, and other tissues due to diabetes, aging, and high-carbohydrate diets have been observed in various animal models. In addition, changes in skin appearance and function have been observed as skin AGE levels increase.
In rats and mice with diabetes induced by the injection of streptozotocin, the levels of AGEs in various tissues, such as blood, skin, liver, and ears, and the glycation of proteins, such as collagen and histone, increased [42,44,46,48,52]. In diabetic animals, the skin permeability and microbial barrier were weakened [46], and inflammation around the wound was worsened [52]. Protein glycation and carbamylation were responsive to diabetes and chronic kidney diseases, respectively, and there was a mutual competition between these two different types of protein modifications [51].
In several animal models, AGE levels in various tissues, such as skin, brain, and aorta, and the glycation of proteins, such as collagen, tended to increase with age [24,25,47,50,53]. This trend differed between breeders and non-breeders in mole-rats: breeders had higher AGE levels but longer lifespans [47]. Between mouse strains, those with higher glycemic levels had higher AGE levels, higher transepidermal water loss (TEWL) rates, stronger inflammatory reactions, lower skin moisture content, and lower collagen content than the other strains, and these differences expanded with age [53]. In lamin B receptor-deficient icJ/icJ mice showing symptoms of premature aging (progeria), AGE levels in the heart and liver were higher than in the control animals, although the differences in skin tissue were not evident [49].
In animal models, high-sugar diets increased AGE levels in blood and skin, increased collagen glycation, decreased collagen solubility, and increased urinary lipid peroxidation product levels [43]. They also increased the expression levels of collagen type I, fibronectin 1, laminin-5, and tenascin C among extracellular matrix proteins and receptors, along with AGE levels in the skin and darkened skin color [54]. On the other hand, they increased sebum secretion and decreased TEWL associated with enhanced fatty acid synthesis [54]. Feeding a high-AGE diet increased the AGE levels in the skin and collagen in diabetic db/db(+/+) mice and delayed skin wound healing [44]. The subcutaneous injection of glycated collagen caused apoptosis of fibroblasts [45].

3.2. Clinical Evidence

As summarized in Table 2, several clinical studies have shown that AGE levels in the blood or skin of human subjects increase due to diabetes, aging, UV irradiation, smoking, etc., and are correlated with skin color and function and the incidence and severity of other diseases or complications.
In clinical trials, HbA1c, one of the glycated forms of Hb, is usually analyzed in human blood samples, and the fingertip skin autofluorescence is often measured as an indicator of AGEs in the skin. In diabetic patients, both blood HbA1c levels and skin autofluorescence tended to increase [55,63] and showed a mutual correlation [59], but there were exceptions [48]. Considering the relatively short lifespan of erythrocytes, AGE levels in the skin may reflect a longer-term accumulation of glycation products than those of Hb [66,67]. In addition, the actual levels of AGEs measured in blood or skin were correlated with the incidence or severity of cognitive impairment, glaucoma, and other diseases, regardless of whether the patient was diagnosed with diabetes [48,62,64].
The skin AGE level increased with age, and it showed a correlation with changes in skin color and muscle strength [57,58]. Skin AGE levels increased due to exposure to UV rays, and oxidative damage to DNA and lipid peroxidation also occurred [60,65]. In diabetic patients, persistent hyperglycemia decreased skin moisture and sebum, but TEWL was reduced in the high HbA1c group, so the effects of AGEs on skin physiology and function may not be straightforward [56].
The AGE level increased while galectin-3 expression was reduced at the edge of the skin wound bed in both diabetic and non-diabetic patients, supporting that galectin-3 may function as a receptor for AGEs involved in AGE clearance, and its absence leads to the accumulation of AGEs [61,68].

4. Interventions for Glycation-Induced Skin Aging

4.1. In Vitro Cell-Free Studies

Table 3 summarizes the selected in vitro studies on the glycation of protein substrates and the effects of potential glycation inhibitors of synthetic and natural origins.
To induce glycation in vitro, a protein substrate and a glycating agent are reacted in an aqueous medium. Albumin, the major protein of blood, and collagen and elastin, the major proteins of the dermis, are frequently used as protein substrates, which provide useful experimental models for glycation reactions in blood and skin, respectively. Glycation agents used include reducing sugars, such as glucose, fructose, and ribose; aldehydes, such as glycolaldehyde and glyceraldehyde; dialdehydes, such as glyoxal and methylglyoxal; and diketones, such as dehydroascorbic acid. The pH of the medium is usually maintained at 7.4 and the temperature at 37 °C to match the biological conditions, but the pH and temperature may be adjusted to accelerate the reaction rate. The total reaction time is adjusted according to the reactivity of the reactants, from several days to several weeks. In the case of a relatively long reaction time, it is common to add a preservative such as NaN3 to prevent changes caused by microorganisms. To quantify AGEs produced through in vitro glycation reactions, fluorescence is usually measured (fluorimetry) [71], although absorbance is often measured (colorimetry) after the nitroblue tetrazolium (NBT) reaction or elastase digestion. In addition, enzyme-linked immunosorbent assays (ELISAs) or dot blots using antibodies immunoreactive to general AGEs or a specific type of AGEs (e.g., CML) are also performed. The increase in protein size resulting from the glycation reaction is confirmed by a decrease in protein mobility in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
In vitro, the glycation reaction is performed to produce protein-AGE adducts (52, 35) or to discover and evaluate inhibitors of the glycation reaction (Table 2). In studies for the latter purpose, AGD or alagebrium (ALT-711) is often used as a positive control. These studies reported that various materials, such as gold nanoparticles [73]; mycosporine-like amino acids [82,87]; N-acetylhydroxyproline [95]; carnosine [80]; phenolic compounds, such as silibinin [76], rosmarinic acid [80], quercetin [81], gallic acid [86], methyl gallate [89], apigenin, chlorogenic acid [90], vanillic acid [92], and flavolignans [83]; alkaloids [85]; polysaccharides [88]; and extracts derived from Manilkara and Argania [75], Silybum marianum flower [76], Akebia quinata fruit [77], Cecropia pachystachya [81], back cumin (Nigella sativa) seed [84], hazelnut (Corylus avellana) skin [86], Cirsium japonicum flower [90], cranberry [93], and chlorella (Parachlorella beijerinckii) [91] significantly inhibited protein glycation reactions. These materials are thought to function as glycation inhibitors that competitively participate in glycation reactions or as antioxidants that inhibit a series of oxidative reactions involved in the production of AGEs.

4.2. In Vitro Studies Using Cultured Cells and Reconstructed Skin Models

Cultured cell models are used to study the pathological responses induced by glycation stress (Table 4). Given their relevance to skin aging, dermal fibroblasts are mainly used, although epidermal keratinocytes and other cell types are also occasionally used [52,97]. Cells are grown into a monolayer on the bottom of a culture plate or a 3-dimensional structure in a collagen gel (for a reconstructed dermis or skin model). Cells are treated with AGES, protein-AGE adducts, or different glycation inducers, such as glyoxal, methylglyoxal, H2O2, etc. These treatments are sometimes combined with UV irradiation.
When cells were exposed to AGEs, protein-AGE adducts, or conditions that increase AGEs (e.g., several glycating agents, t-butylhydroperoxide, H2O2, or UV radiation), cell senescence or death (apoptosis) increased [50,77,109,111]. ROS production increased [77,79], and antioxidant enzymes decreased [111], leading to increased oxidative stress and endoplasmic reticulum stress [50]. RAGE expression increased [79,110], and various cell signaling pathways were activated, resulting in the increased expression of inflammatory cytokines [79,109,111]. Gene expression of matrix metalloproteinases (MMPs) increased, whereas collagen gene expression decreased, resulting in the lowered collagen level [79,90,105,109,111]. These changes were further amplified by the combination of glycating agents and ultraviolet irradiation [96].
The glycation-induced changes in human dermal fibroblasts (HDFs) were reversed by various interventions, including AGD [109]; N-acetylcysteine [50]; carnosine [103,107]; supramolecular carnosine [110]; polyphenolic compounds, such as plantamajoside [79], resveratrol, oxyresveratrol, piceatannol [107], plant extracts derived from Akebia quinata fruit [77], and unripe Carica papaya fruit [109]; hydrolyzed fish collagen [104]; and the K formulation containing hyaluronan and collagen peptide [111]. In HaCaT keratinocytes, sunflower sprout extract inhibited AGE formation induced by UVA irradiation [106], and plantamajoside attenuated ROS production and the inflammatory response induced by bovine serum albumin (BSA)-AGE adducts and UVB irradiation [79]. Pholiota nameko polysaccharides and Djulis (Chenopodium formosanum) extract attenuated ROS production and enhanced the viability of Hs68 cells treated with methylglyoxal or CML [88,105]. Vanillic acid enhanced the viability of RAW264.7 cells exposed to methylglyoxal [92]. Hazelnut (Corylus avellana) skin extract and carnosine improved the vitality and phagocytic function of macrophages derived from THP-1 cells in removing senescent cells [94,103].
The antiglycation effects of Jasminum sambac cell extract were observed in an experimental model in which cultured cells were fixed with formalin and then treated with glyoxal to explore the production of AGEs [108]. Chemical changes due to glycation can be studied using dead dermis, which is prepared by killing the cells of the separated skin and removing the epidermis. UV irradiation caused the production of ROS and an increase in AGEs in the dead dermis, and these changes were alleviated by AGD and Argania extract [75]. Glyoxal treatment of mouse skin explants without cultivation caused the yellowing of skin color and increased TEWL, suggesting that glycation causes aesthetic and functional changes in the skin [97].
In a reconstructed dermis model in which HDFs were embedded in a three-dimensional collagen gel, the collagen gel contracted as the cells grew, whereas the change was inhibited in the glyoxal-treated collagen gel [91]. Chlorella (Parachlorella beijerinckii) extract, AGD, and N-acetylhydroxyproline inhibited the production of AGEs and recovered the cell-mediated collagen contraction [91,95].
The effects of collagen glycation have been studied in a reconstructed skin model with a stratified structure in which dermal keratinocytes are grown on top of a dermal-like structure after HDFs are grown in a collagen matrix with or without glycation [74,78,98,112]. Ribose-induced glycation of collagen inhibited the contraction of the collagen lattice, increasing the epidermal thickness and decreasing the dermal thickness of a reconstructed skin model [85,112]. Ribose increased CML levels and extended the suprabasal integrin β1 expression, whereas most of these changes were attenuated by AGD or blueberry extract [71]. In the skin model (MimeskinTM, BASF BC, Lyon, France) reconstructed with ribose-treated collagen, the diameters of collagen fibers were reduced, and cell growth and layer formation were inhibited, but these changes were alleviated by AGD and Davilla extract with anti-glycation effects [75]. AGD or several alkaloids from Ocotea Paranapiacabensis inhibited the thinning of the dermal layer in skin models reconstructed using different glycated collagens [78,85].
In an endothelialized and innervated reconstructed skin model prepared from collagen-chitosan sponge seeded with HDFs, human umbilical vein endothelial cells (HUVECs), sensory neurons from the dorsal root ganglia of mouse embryos, and human epidermal keratinocytes, glyoxal increased CML and decreased the number of capillaries and the expression of angiogenesis markers, such as platelet endothelial cell adhesion molecule (PECAM) 1, loricrin, filaggrin, and Krüppel-like factor (KLF) 4, and these changes were attenuated by AGD but not alagebrium (ALT-711) [101].
In a full-thickness skin model (EpiDermFT, MatTek Life Sciences, Ashland, MA, USA), carnosine, resveratrol, oxyresveratrol, and piceatannol attenuated the cellular and structural changes induced by glycation stress [107].

4.3. Ex Vivo Studies

Human skin explants provide an ex vivo model that allows observation of the histological changes due to glycation stress imposed during the subsequent cultivation (Table 5).
Methylglyoxal increased the expression of CML during culture period, while decreasing the expression of fibrillin-1 protein [76,77,108], a component of microfibrils present in oxytalan fibers at the dermo-epidermal junction [116]. These changes were alleviated by AGD, carnosine, methyl gallate, and extracts of Silybum marianum flowers, Akebia quinata fruits, Jasminum sambac cells, and Dunaliella salina [76,77,89,108,113,114]. In skin specimens, glucose or glycolaldehyde treatment increased autofluorescence, which was reduced by incubation with N-acetylhydroxyproline [95] or deglycating enzymes, such as fructosamine 3-kinase and fructosyl-amino acid oxidase [115]. Fructosamine 3-kinase further improved the elasticity of hypertrophic scar tissue ex vivo [115].

4.4. In Vivo Animal Studies

Table 6 summarizes selected in vivo studies that explored the effects of various interventions on AGE accumulation and pathological changes induced by aging, diabetes, high-dose sugar administration, UV irradiation, etc.
In rats with streptozotocin-induced diabetes, AGD, rutin, and vanillic acid reduced the AGE levels in the skin [92,117]. Streptozotocin-induced diabetes in hairless mice increased skin AGE levels and wrinkles and decreased skin hydration and elasticity; these changes were attenuated by an AGE blocker containing goji berry, fig, and Korean mint extracts [135]. Red blood cell-immunoglobulin (Ig) G crosslinking and tail tendon collagen crosslinking increased in Lewis rats with streptozotocin-induced diabetes, whereas the oral administration of ALT-711, an AGE breaker, reduced these changes [36]. Topical lotion containing ALT-711 improved skin elasticity and hydration in Fischer 344 rats [36]. On the other hand, AGE-breakers, such as N-phenacylthiazolium and N-phenylacy-4,5-dimethylthiazolium halides, or pyridoxamine had no effects on the crosslinking of skin collagen and acid-solubility of tail collagen affected by streptozotocin-induced diabetes in rats [37].
In rats, mice, chicks, and monkeys, dietary restriction reduced the increase in the levels of AGEs, such as furosine, CML, and pentosidine, in the skin or skin collagen induced by chronological aging [26,119,120,122,128]. In Emory mice prone to age-related cataracts, dietary restriction reduced cataract grade and dermatological lesions and shortened the tail tendon breakdown time [118]. AGD, vitamins C and E, and green tea extracts had little or weak effects on skin AGE levels and tail tendon breakdown time in aging rats [126,127]. The increments in the AGE level due to aging and the effect of dietary restriction were smaller in the aorta and blood than in the skin [120]. The type of carbohydrates (cornstarch, sucrose, glucose, fructose, or a combination of glucose and fructose) in the diet had little effect on serum glycemic stress and AGE levels, whereas overall calorie restriction had significant effects in aging Fischer 344 rats [124].
In mice orally administered high-dose glucose, blood glucose levels were unchanged, but AGE levels in the subcutaneous tissue were elevated, microvessel diameters were reduced, and vascular lesions were increased; these changes were alleviated by drinking water containing AGD [121]. In mice administered high concentrations of galactose, blood AGE levels were elevated, and cognitive impairment was aggravated, which was alleviated by AGD [123]. In addition, the increase in skin AGE levels by galactose was accompanied by increased oxidative stress, decreased collagen expression and dermal thickness, and inhibition of microvascular development, and these skin aging-related changes were alleviated by adiposepderived stem cell injection [129,130]. Lactobacillus fermentum CQPC04-fermented soy milk and dapagliflozin (a medication used to treat type 2 diabetes) exhibited antioxidant, anti-inflammatory, and antiglycation effects in the skin and enhanced dermal collagen or hyaluronan in mice administered high galactose [132,136].
In UV-irradiated mice, the skin level of AGEs was reduced by Schizonepeta tenuifolia extract (containing rosmarinic acid) and idebenone-loaded nanoparticles [133,134]. In addition, Schizonepeta tenuifolia extract improved skin wrinkles, hydration, and the dermal levels of collagen and hyaluronan, and idebenone-loaded nanoparticles showed skin-whitening and antioxidant effects [133,134]. Mycosporine-like amino acid-containing emulsions enhanced the expression levels of antioxidant enzymes, such as SOD and CAT, in the ear skin irradiated with UV, although it had no significant effects on the skin AGE levels in DBA/2CrSlc mice [87].
In chicks, allopurinol injections reduced uric acid, which has antioxidant activity, causing oxidative stress, while hemin reduced uric acid, but both increased pentosidine in the skin and were relieved by dietary restriction [125].

4.5. Clinical Studies

Dietary and topical agents with antioxidant and antiglycation activities have been tested in clinical studies to address their effects on skin aging (Table 7).
The clinical effects of dietary supplements containing synthetic or natural substances with antioxidant and antiglycation activities on human skin aging parameters vary widely. In diabetic patients, dietary supplementation with vitamins E and C with antioxidant activity had no significant effect on skin AGE levels [137]. The oral intake of a capsule containing vitamins, amino acids, and carnosine with antiglycation activity improved skin surface parameters compared to the placebo control group [140]. An equol supplement containing S-equol and several other natural phenolic compounds did not improve skin aging parameters nor AGE levels, although it improved climactic symptoms in post-menopausal women [141]. Fish-derived collagen peptides reduced skin AGE levels and insulin resistance indices compared to the placebo control group [142]. Twelve weeks of intake of capsules containing rosemary extract reduced the levels of 4-hydroxynonenal-protein adducts and AGEs in the skin, supporting its antioxidant and antiglycation activity [144]. A green tea oral supplement had no significant effects on skin aging parameters even when its intake was combined with the topical application of a cream containing green tea extract enriched with (−)-epigallocatechin gallate and other phenolic compounds [138].
Several topical formulations have shown significant efficacy in improving human skin aging parameters. A topical formulation containing C-xylose and glycation-inhibitory blueberry extract mitigated skin aging symptoms, although the skin AGE level was not reduced significantly [139]. A cream containing glycation-inhibitory Argania plant extract, α-tocopheryl acetate, rutin, and ferulic acid lowered free radical production as measured by UVA-induced chemiluminescence [75]. An ampule containing hydrolyzed fish collagen (25% tripeptide) reduced skin AGE levels and improved periorbital and glabellar skin wrinkles, skin surface elasticity, and dermal density [104]. A gel cream containing Dunaliella salina extract rich in colorless carotenoids (phytoene and phytofluene) reduced skin AGE levels and inflammatory skin reactivity to histamine stimulation while improving skin aging parameters, including periocular wrinkles and red spots [114]. A lotion containing Cirsium japonicum flower extract also improved skin aging parameters [90].
A serum containing sunflower sprout extract exhibited antiglycation activity in cells and anti-inflammatory effects in an ex vivo model and improved facial skin conditions, such as radiance, smoothness, fine lines of crow’s feet, and overall eye appearance, in a human study [106]. An essence containing supramolecular carnosine with antiglycation activity reduced brown spots and the melanin index in the face and brightened the skin tone [110].

5. Discussion

5.1. Skin Anti-Aging Strategies Targeting Glycation

Glycation stress and oxidative stress are interconnected conditions with overlapping mechanisms of action, yet they also exhibit distinct effects. Oxidative stress due to an increase in prooxidants (e.g., ROS) and a decrease in antioxidants and antioxidant enzymes causes oxidative damage to proteins, lipids, and nucleic acids [145]. In contrast, glycation stress causes chemical modifications of proteins, lipids, and nucleic acids by sugars (glucose, fructose, and galactose), their metabolites, or their breakdown products [15]. On the protein side, protein carbonyls are formed via oxidation [24], and protein-AGE adducts are formed via glycation or glycoxidation [126], which are distinct from another type of protein modification, carbamylation [51]. Because of the mechanistic redundancy of glycation stress versus oxidative stress, in principle, many known antioxidants may be used in alleviating glycation stress and the associated skin aging [146,147,148]. Currently, targeting glycation with competitive glycation inhibitors or antioxidants is considered to be a practical and feasible skin anti-aging strategy [149,150].
It is necessary to recognize that glycation stress may be crucial, especially in patients with diabetes, older people, and people who mainly eat carbohydrate-based meals. These people are advised to reduce high-carbohydrate diets, high-AGE diets, and UV exposure or to increase physical activity in addition to medical management [151,152,153]. It is clear that eliminating the cause of glycation stress through disease management and lifestyle modification is the primary option for glycation-induced skin aging. A secondary option may be the appropriate use of dietary supplements or topical formulations containing anti-glycation agents or antioxidants. Multiple levels of evidence from in vitro, ex vivo, in vivo, and clinical studies over the past 30 years support that glycation-induced skin aging can be mitigated by certain synthetic and natural agents with antiglycation and/or antioxidant activity (Figure 1).
In vitro experiments showed that several synthetic compounds, natural products, and plant extracts had anti-glycation activity (Table 3). In experiments using cultured cells, glycation stress increased ROS production, the gene expression of inflammatory cytokines, and cell death or senescence, which were suppressed by several synthetic and natural agents (Table 4). In reconstructed skin models prepared using glycated collagen, cell-mediated collagen contraction was impaired, and dermal thickness was reduced, whereas these changes were partially restored to normal by several synthetic and natural agents (Table 4). In ex vivo experiments using human skin explants, several natural and synthetic agents restored the expression of fibrillin-1 at the dermo-epidermal junction, reduced by glycation stress (Table 5).
In animal models, glycation stress due to diabetes, aging, high-carbohydrate diets, UV radiation, and oxidative stress increased AGE levels in the blood or skin and oxidative damage to blood or skin, decreased dermal thickness and the dermal contents of collagen and hyaluronan, and prolonged the tail tendon breakdown time (Table 1 and Table 6). Dietary restriction, oral and topical administration of synthetic or natural agents, and other interventions reversed these changes and alleviated glycation-induced dermal lesions or skin aging symptoms (Table 6). In clinical trials, several dietary supplements or topical formulations containing vitamins, amino acids, peptides, plant extracts, or phytochemicals reduced skin autofluorescence (or the AGE level), which was increased by diabetes, aging, high-carbohydrate diets, or UV irradiation (Table 2 and Table 7). They also improved skin aging parameters, such as skin tone, wrinkles, elasticity, and hydration, in human subjects (Table 7).

5.2. Synthetic and Natural Agents Targeting Glycation

There are several synthetic compounds that inhibit the formation of AGEs or decompose preformed AGEs, with studies supporting or questioning their therapeutic potential and safety. AGD has been used as a positive control substance in many studies and exhibits various biological effects but is not clinically used due to concerns about insufficient safety/efficacy balance or off-target effects [126,154]. Alagebrium (ALT-711), the first AGE-breaker, and later version compounds, such as N-phenacylthiazolium and N-phenylacy-4,5-dimethylthiazolium halides, also had similar shortcomings, limiting their applications [37,155].
Various other synthetic compounds, such as amino acids or derivatives (e.g., histidine, methionine, N-acetylcysteine, N-acetylhydroxyproline), peptides (e.g., carnosine, supramolecular carnosine), vitamins or their derivatives [e.g., vitamin B5 (pantothenic acid), pantethine, vitamin B6 (pyridoxine, pyridoxamine), vitamin C (ascorbic acid), vitamin E (α-tocopherol), α-tocopheryl acetate], and drugs (e.g., dapagliflozin), have been studied for application to glycation-induced skin aging, but their efficacy has not yet been well proven [137].
Among natural agents, phenolic compounds distributed in plants (e.g., rutin, quercetin, apigenin, rosmarinic acid, gallic acid, methyl gallate, vanillic acid, chlorogenic acid, ferulic acid, S-equol, resveratrol, oxyresveratrol, piceatannol, silibinin, plantamajoside) have been studied extensively for their antiglycation and skin anti-aging effects. Mycosporine-like amino acids derived from algae (e.g., Agarophyton chilense, Pyropia plicata, Champia novaezelandiae, Bostrychia scorpioides) or cyanobacteria (e.g., Aphanothece halophytica), flavonolignans derived from plants (e.g., Silybum marianum), alkaloids derived from plants (e.g., Ocotea paranapiacabensis), polysaccharides derived from mushrooms (e.g., Pholiota nameko) or bacteria (e.g., Klebsiella pneumonia, Klebsiella planticola), fish (e.g., Pangasius hypophthalmus)-derived collagen hydrolysates, and Lactobacillus fermentum-fermented soy milk have been studied for their applications in similar contexts.
Extracts from various plants have been studied with respect to glycation-induced skin aging, including Akebia quinata (Chocolate vine) fruit, Argania spinosa (Argan), Agastache rugose (Korean mint), Camellia sinensis (Green tea), Carica papaya (Papaya) fruit, Cecropia pachystachya (Ambay pumpwood) leaf, Chenopodium formosanum (Djulis), Cirsium japonicum (Japanese thistle) flower, Corylus avellana skin (Hazelnut), Davilla rugosa (Davilla), Ficus carica (Fig), Helianthus annuus (Sunflower) sprout, Jasminum sambac (Arabian jasmine) cell, Lycium chinense (Goji berry), Manilkara multinervis (African Manilkara), Nigella sativa (Black cumin) seed, Rosmarinus officinalis (Rosemary) leaf, Schizonepeta tenuifolia (Japanese catnip), Silybum marianum (Milk thistle) flower, and Vaccinium angustifolium (Blueberry). Additionally, microalgae, such as Dunaliella salina (Dunaliella) and Parachlorella beijerinckii (Chlorella), have also been studied for their antiglycation and anti-aging properties.
Although the therapeutic potential of many natural products on skin glycation and aging has been supported by previous studies, there have been exceptional observations as well [138,139]. In addition, since the experimental data of each natural product have been provided in individual studies, it is difficult to make a relative comparison between their efficacies. Furthermore, clinical trials to verify their skin anti-aging efficacy are mostly lacking.

5.3. Mechanistic Insights and Therapeutic Applications

Skin aging due to glycation stress can occur in both the epidermis and dermis [19,41]. Glycation stress increases the level of fluorescing yellowish AGEs in the epidermis and the cross-linking between the dermal matrix components, such as collagen, elastin, and hyaluronan. As a result, the skin color turns more yellowish and darker, the skin surface becomes rougher, and wrinkles increase and deepen. In addition, the dermis layer becomes thinner and harder, and elasticity decreases. Glycation stress can damage the skin barrier and increase TEWL rates [53,97,156], with some exceptional cases [54,56]. Therefore, skin aging due to glycation stress is recognizable by the aesthetic, physical, and functional changes of the skin.
If we divide the process of glycation causing skin aging into two parts, the first step is the production of new AGEs through chemical reactions, and the second step is the occurrence of biological effects induced by existing AGEs (Figure 2). In the first step, when a glycation agent reacts with a substrate, the reaction is affected by oxygen, catalytic metals, UV rays, etc. [157,158]. In the second step, AGEs cause oxidative stress and stimulate RAGE-mediated cell signaling pathways, resulting in the upregulation of inflammatory cytokines and the downregulation of collagen. Overall, glycation stress leads to cell death or senescence, inflammation, and skin aging. Therefore, various treatment strategies against glycation-induced skin aging can be envisioned, such as strategy 1 to prevent the production of AGEs, strategy 2 to remove the preformed AGEs, strategy 3 to control RAGE-mediated cell signaling pathways leading to the upregulation of inflammatory gene expression and downregulation of collagen gene expression, strategy 4 to assist or enhance cellular antioxidant defense, and strategy 5 to regenerate cells and matrix environments.
For the successful clinical application of these strategies, the discovery and development of synthetic compounds, natural products, or other preparations suitable for each individual strategy must be a prerequisite. It is recommended that dietary supplements or topical formulations applied for human anti-aging purposes include at least one active component optimized for each strategy. Furthermore, it is also advantageous to apply multiple strategies in combination. Additionally, if possible, it may also be advantageous to apply oral supplements and topical formulations simultaneously. In any case, it is essential to check safety in advance. In clinical trials, the analysis of skin AGE levels along with various skin parameters should be conducted to verify whether the antiglycation intervention was performed properly. The level of AGEs in the skin can be conveniently quantified by measuring skin autofluorescence [66,143,159,160,161]. This method has the advantage of being noninvasive and minimally affected by the interference of other skin pigments such as melanin [162,163].

5.4. Future Tasks and Prospects

Developing technologies to implement the five therapeutic strategies to alleviate glycation-induced skin aging will be an important and necessary future task. Various glycation inhibitors for strategy 1 have been discovered in separate studies, making it difficult to know which one is better. An integrated study comparing their efficacy and safety with a set of criteria in the same experimental model is needed. For strategy 2, due to the questionable safety and efficacy of existing synthetic AGE-breakers [101,155], future studies are needed to develop alternative innovative therapies involving deglycating enzymes [115,164], oxidized protein hydrolases [165,166], or physical disruption of AGEs [167,168,169]. Additionally, we anticipate the development of drugs that promote the removal of AGEs by cell-mediated phagocytosis [103]. For strategy 3, although various synthetic and natural modulators are known to modulate the RAGE-mediated cell signaling pathways [170,171], many tasks remain to be implemented, including the assessment of safety, efficacy, pharmacodynamics, and pharmacokinetics in vivo. For strategy 4, various types of synthetic or natural antioxidants [172] and modulators of nuclear factor erythroid 2-related factor (NRF) 2 may be used to assist or enhance cellular antioxidant defense systems [173]. Future studies are needed to verify their efficacy in vivo before clinical application. Strategy 5 is the most challenging, but various attempts have already been made to help the regeneration of cells and matrix environments by injecting cells [129,130], matrix components [174], or skin boosters [175]. Developing advanced nanomaterials for the control of glycation stress is also an important future task for implementing these treatment strategies [73,134,176].
It is predicted that future skin anti-aging treatments will be led by targeted and tailored therapies that are supposed to vary by the specific cause of skin aging and the individual health condition of the subject. Such glycation-targeting treatments will be particularly important for patients who are more affected by glycation stress. In other words, the treatments will have a significant impact on skin aging only in subjects with a high skin AGE level. Therefore, for the best outcomes, the selection of the right treatment subjects is as important as the selection of the right treatment options. It is also important to measure skin AGE levels before and after treatments to check the quantitative changes due to the applied intervention. The data will be essential to claim the skin-anti-aging effects of a certain intervention targeting AGEs. The glycation-targeting technologies would have expanding applications in various skin inflammatory conditions (e.g., psoriasis, atopic dermatitis), metabolic complications (e.g., diabetic dermopathy, impaired wound healing), and age-related pathologies (e.g., elastosis, dyschromia).

6. Conclusions

Many pieces of experimental and clinical evidence support the significance of glycation-induced skin aging. Several synthetic and natural agents with antiglycation or antioxidant activity reduce skin AGE levels, oxidative damage, and skin aging symptoms caused by chronological aging, diabetes, high-carbohydrate diets, UV radiation, or oxidative stress. Therefore, it is suggested that glycation-targeting dietary supplements or topical formulations containing these agents may provide therapeutic options to mitigate glycation-induced skin aging.

Author Contributions

Conceptualization, Y.C.B.; investigation, J.Y.C.; writing—original draft preparation, J.Y.C. and Y.C.B.; writing—review and editing, N.G.H. and W.J.L.; supervision, Y.C.B. and W.J.L.; project administration, N.G.H.; funding acquisition, W.J.L., Y.C.B. and N.G.H. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: RS-2024-00437643).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The original contributions presented in this study are included in the article, and further inquiries can be directed to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

AGDaminoguanidine
AGEadvanced glycation end-product
AKTprotein kinase B; AKT
BSAbovine serum albumin
CATcatalase
CCRC-C chemokine receptor
CELNε-(carboxyethyl)lysine
CKcytokeratin
CMANω-(carboxymethyl)arginine
CMLNε-(carboxymethyl)lysine
COLcollagen
COXcyclooxygenase
DTPAdiethylenetriaminepentaacetic acid
ELISAenzyme-linked immunosorbent assay
ERKextracellular signal-regulated kinase
GPXglutathione peroxidase
Hbhemoglobin
HDFhuman dermal fibroblast
HEKhuman epidermal keratinocyte
HUVEChuman umbilical vein endothelial cell
Igimmunoglobulin
IκBinhibitor of NF-κB
ILinterleukin
ITAoindividual topology angle
JNKc-Jun N-terminal kinase
KLFkrüppel-like factor
LTleukotriene
MAPKmitogen-activated protein kinase
MCPmonocyte chemoattractant protein
MDAmalondialdehyde
MG-H1methylglyoxal-derived hydroimidazolone 1; Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine
MMPmatrix metalloproteinase
MPOmyeloperoxidase
NBTnitroblue tetrazolium
NFnuclear factor
NRFnuclear factor erythroid 2-related factor
PBSphosphate-buffered saline
PECAMplatelet endothelial cell adhesion molecule
PGprostaglandin
PMSFphenylmethylsulfonyl fluoride
RAGEreceptor for advanced glycation end-products
ROSreactive oxygen species
RTroom temperature
SA-β-galsenescence-associated β-galactosidase
SDS-PAGEsodium dodecyl sulfate-polyacrylamide gel electrophoresis
SIRTNAD-dependent deacetylase sirtuin
SODsuperoxide dismutase
TEWLtransepidermal water loss
TNFtumor necrosis factor
UVultraviolet
VEGFvascular endothelial growth factor

References

  1. Hussein, R.S.; Bin Dayel, S.; Abahussein, O.; El-Sherbiny, A.A. Influences on Skin and Intrinsic Aging: Biological, Environmental, and Therapeutic Insights. J. Cosmet. Dermatol. 2025, 24, e16688. [Google Scholar] [CrossRef] [PubMed]
  2. Tobin, D.J. Introduction to skin aging. J. Tissue Viability 2017, 26, 37–46. [Google Scholar] [CrossRef]
  3. Bonté, F.; Girard, D.; Archambault, J.C.; Desmoulière, A. Skin Changes During Ageing. Subcell. Biochem. 2019, 91, 249–280. [Google Scholar] [CrossRef]
  4. Russell-Goldman, E.; Murphy, G.F. The Pathobiology of Skin Aging: New Insights into an Old Dilemma. Am. J. Pathol. 2020, 190, 1356–1369. [Google Scholar] [CrossRef]
  5. Wong, Q.Y.A.; Chew, F.T. Defining skin aging and its risk factors: A systematic review and meta-analysis. Sci. Rep. 2021, 11, 22075. [Google Scholar] [CrossRef] [PubMed]
  6. Farage, M.A.; Miller, K.W.; Elsner, P.; Maibach, H.I. Intrinsic and extrinsic factors in skin ageing: A review. Int. J. Cosmet. Sci. 2008, 30, 87–95. [Google Scholar] [CrossRef] [PubMed]
  7. Krutmann, J.; Schikowski, T.; Morita, A.; Berneburg, M. Environmentally-Induced (Extrinsic) Skin Aging: Exposomal Factors and Underlying Mechanisms. J. Investig. Dermatol. 2021, 141, 1096–1103. [Google Scholar] [CrossRef]
  8. Boo, Y.C. Emerging Strategies to Protect the Skin from Ultraviolet Rays Using Plant-Derived Materials. Antioxidants 2020, 9, 637. [Google Scholar] [CrossRef] [PubMed]
  9. Boo, Y.C. Can Plant Phenolic Compounds Protect the Skin from Airborne Particulate Matter? Antioxidants 2019, 8, 379. [Google Scholar] [CrossRef]
  10. He, X.; Gao, X.; Xie, W. Research Progress in Skin Aging, Metabolism, and Related Products. Int. J. Mol. Sci. 2023, 24, 15930. [Google Scholar] [CrossRef]
  11. Grenier, A.; Morissette, M.C.; Rochette, P.J.; Pouliot, R. The combination of cigarette smoke and solar rays causes effects similar to skin aging in a bilayer skin model. Sci. Rep. 2023, 13, 17969. [Google Scholar] [CrossRef]
  12. Kierans, S.J.; Taylor, C.T. Glycolysis: A multifaceted metabolic pathway and signaling hub. J. Biol. Chem. 2024, 300, 107906. [Google Scholar] [CrossRef]
  13. Yamagishi, S.; Maeda, S.; Matsui, T.; Ueda, S.; Fukami, K.; Okuda, S. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim. Biophys. Acta. 2012, 1820, 663–671. [Google Scholar] [CrossRef] [PubMed]
  14. Singh, V.P.; Bali, A.; Singh, N.; Jaggi, A.S. Advanced glycation end products and diabetic complications. Korean J. Physiol. Pharmacol. Off. J. Korean Physiol. Soc. Korean Soc. Pharmacol. 2014, 18, 1. [Google Scholar] [CrossRef] [PubMed]
  15. Uceda, A.B.; Mariño, L.; Casasnovas, R.; Adrover, M. An overview on glycation: Molecular mechanisms, impact on proteins, pathogenesis, and inhibition. Biophys. Rev. 2024, 16, 189–218. [Google Scholar] [CrossRef]
  16. Crisan, M.; Taulescu, M.; Crisan, D.; Cosgarea, R.; Parvu, A.; Cãtoi, C.; Drugan, T. Expression of advanced glycation end-products on sun-exposed and non-exposed cutaneous sites during the ageing process in humans. PLoS ONE 2013, 8, e75003. [Google Scholar] [CrossRef] [PubMed]
  17. Isami, F.; West, B.J.; Nakajima, S.; Yamagishi, S.I. Association of advanced glycation end products, evaluated by skin autofluorescence, with lifestyle habits in a general Japanese population. J. Int. Med. Res. 2018, 46, 1043–1051. [Google Scholar] [CrossRef]
  18. van de Zande, S.C.; de Vries, J.K.; van den Akker-Scheek, I.; Zwerver, J.; Smit, A.J. A physically active lifestyle is related to a lower level of skin autofluorescence in a large population with chronic disease (LifeLines cohort). J. Sport. Health Sci. 2022, 11, 260–265. [Google Scholar] [CrossRef]
  19. Wang, L.; Jiang, Y.; Zhao, C. The effects of advanced glycation end-products on skin and potential anti-glycation strategies. Exp. Dermatol. 2024, 33, e15065. [Google Scholar] [CrossRef]
  20. Masaki, H.; Okano, Y.; Sakurai, H. Generation of active oxygen species from advanced glycation end-products (AGE) under ultraviolet light A (UVA) irradiation. Biochem. Biophys. Res. Commun. 1997, 235, 306–310. [Google Scholar] [CrossRef]
  21. Twarda-Clapa, A.; Olczak, A.; Białkowska, A.M.; Koziołkiewicz, M. Advanced Glycation End-Products (AGEs): Formation, Chemistry, Classification, Receptors, and Diseases Related to AGEs. Cells 2022, 11, 1312. [Google Scholar] [CrossRef]
  22. Zhang, Q.; Ames, J.M.; Smith, R.D.; Baynes, J.W.; Metz, T.O. A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: Probing the pathogenesis of chronic disease. J. Proteome Res. 2009, 8, 754–769. [Google Scholar] [CrossRef]
  23. Chellan, P.; Nagaraj, R.H. Early glycation products produce pentosidine cross-links on native proteins. novel mechanism of pentosidine formation and propagation of glycation. J. Biol. Chem. 2001, 276, 3895–3903. [Google Scholar] [CrossRef] [PubMed]
  24. Nowotny, K.; Grune, T. Degradation of oxidized and glycoxidized collagen: Role of collagen cross-linking. Arch. Biochem. Biophys. 2014, 542, 56–64. [Google Scholar] [CrossRef]
  25. Kinoshita, S.; Mera, K.; Ichikawa, H.; Shimasaki, S.; Nagai, M.; Taga, Y.; Iijima, K.; Hattori, S.; Fujiwara, Y.; Shirakawa, J.I.; et al. N(ω)-(Carboxymethyl)arginine Is One of the Dominant Advanced Glycation End Products in Glycated Collagens and Mouse Tissues. Oxid. Med. Cell Longev. 2019, 2019, 9073451. [Google Scholar] [CrossRef] [PubMed]
  26. Cefalu, W.T.; Bell-Farrow, A.D.; Wang, Z.Q.; Sonntag, W.E.; Fu, M.X.; Baynes, J.W.; Thorpe, S.R. Caloric restriction decreases age-dependent accumulation of the glycoxidation products, N epsilon-(carboxymethyl)lysine and pentosidine, in rat skin collagen. J. Gerontol. A Biol. Sci. Med. Sci. 1995, 50, B337–B341. [Google Scholar] [CrossRef] [PubMed]
  27. Lohwasser, C.; Neureiter, D.; Weigle, B.; Kirchner, T.; Schuppan, D. The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. J. Invest. Dermatol. 2006, 126, 291–299. [Google Scholar] [CrossRef]
  28. Lee, E.J.; Kim, J.Y.; Oh, S.H. Advanced glycation end products (AGEs) promote melanogenesis through receptor for AGEs. Sci. Rep. 2016, 6, 27848. [Google Scholar] [CrossRef]
  29. Serban, A.I.; Stanca, L.; Geicu, O.I.; Munteanu, M.C.; Dinischiotu, A. RAGE and TGF-β1 Cross-Talk Regulate Extracellular Matrix Turnover and Cytokine Synthesis in AGEs Exposed Fibroblast Cells. PLoS ONE 2016, 11, e0152376. [Google Scholar] [CrossRef]
  30. Perrone, A.; Giovino, A.; Benny, J.; Martinelli, F. Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects. Oxid. Med. Cell Longev. 2020, 2020, 3818196. [Google Scholar] [CrossRef]
  31. Wautier, M.P.; Chappey, O.; Corda, S.; Stern, D.M.; Schmidt, A.M.; Wautier, J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 2001, 280, E685–E694. [Google Scholar] [CrossRef]
  32. Daffu, G.; del Pozo, C.H.; O’Shea, K.M.; Ananthakrishnan, R.; Ramasamy, R.; Schmidt, A.M. Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int. J. Mol. Sci. 2013, 14, 19891–19910. [Google Scholar] [CrossRef] [PubMed]
  33. Hammes, H.P.; Strödter, D.; Weiss, A.; Bretzel, R.G.; Federlin, K.; Brownlee, M. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia 1995, 38, 656–660. [Google Scholar] [CrossRef] [PubMed]
  34. Loske, C.; Neumann, A.; Cunningham, A.M.; Nichol, K.; Schinzel, R.; Riederer, P.; Münch, G. Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress. J. Neural Transm. 1998, 105, 1005–1015. [Google Scholar] [CrossRef]
  35. Kuzan, A. Toxicity of advanced glycation end products (Review). Biomed. Rep. 2021, 14, 46. [Google Scholar] [CrossRef] [PubMed]
  36. Vasan, S.; Foiles, P.; Founds, H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch. Biochem. Biophys. 2003, 419, 89–96. [Google Scholar] [CrossRef]
  37. Yang, S.Z.; Litchfield, J.E.; Baynes, J.W. AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. Arch. Biochem. Biophys. 2003, 412, 42–46. [Google Scholar] [CrossRef]
  38. Cheng, G.; Wang, L.L.; Qu, W.S.; Long, L.; Cui, H.; Liu, H.Y.; Cao, Y.L.; Li, S. C16, a novel advanced glycation endproduct breaker, restores cardiovascular dysfunction in experimental diabetic rats. Acta Pharmacol. Sin. 2005, 26, 1460–1466. [Google Scholar] [CrossRef]
  39. Bakris, G.L.; Bank, A.J.; Kass, D.A.; Neutel, J.M.; Preston, R.A.; Oparil, S. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am. J. Hypertens. 2004, 17, 23S–30S. [Google Scholar] [CrossRef]
  40. Song, Q.; Liu, J.; Dong, L.; Wang, X.; Zhang, X. Novel advances in inhibiting advanced glycation end product formation using natural compounds. Biomed. Pharmacother. 2021, 140, 111750. [Google Scholar] [CrossRef]
  41. Chen, C.Y.; Zhang, J.Q.; Li, L.; Guo, M.M.; He, Y.F.; Dong, Y.M.; Meng, H.; Yi, F. Advanced Glycation End Products in the Skin: Molecular Mechanisms, Methods of Measurement, and Inhibitory Pathways. Front. Med. 2022, 9, 837222. [Google Scholar] [CrossRef]
  42. Gugliucci, A.; Bendayan, M. Histones from diabetic rats contain increased levels of advanced glycation end products. Biochem. Biophys. Res. Commun. 1995, 212, 56–62. [Google Scholar] [CrossRef]
  43. Levi, B.; Werman, M.J. Long-term fructose consumption accelerates glycation and several age-related variables in male rats. J. Nutr. 1998, 128, 1442–1449. [Google Scholar] [CrossRef] [PubMed]
  44. Peppa, M.; Brem, H.; Ehrlich, P.; Zhang, J.G.; Cai, W.; Li, Z.; Croitoru, A.; Thung, S.; Vlassara, H. Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes 2003, 52, 2805–2813. [Google Scholar] [CrossRef]
  45. Alikhani, Z.; Alikhani, M.; Boyd, C.M.; Nagao, K.; Trackman, P.C.; Graves, D.T. Advanced Glycation End Products Enhance Expression of Pro-apoptotic Genes and Stimulate Fibroblast Apoptosis through Cytoplasmic and Mitochondrial Pathways. J. Biol. Chem. 2005, 280, 12087–12095. [Google Scholar] [CrossRef] [PubMed]
  46. Park, H.Y.; Kim, J.H.; Jung, M.; Chung, C.H.; Hasham, R.; Park, C.S.; Choi, E.H. A long-standing hyperglycaemic condition impairs skin barrier by accelerating skin ageing process. Exp. Dermatol. 2011, 20, 969–974. [Google Scholar] [CrossRef] [PubMed]
  47. Dammann, P.; Sell, D.R.; Begall, S.; Strauch, C.; Monnier, V.M. Advanced glycation end-products as markers of aging and longevity in the long-lived Ansell’s mole-rat (Fukomys anselli). J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67, 573–583. [Google Scholar] [CrossRef]
  48. Yamanaka, M.; Matsumura, T.; Ohno, R.; Fujiwara, Y.; Shinagawa, M.; Sugawa, H.; Hatano, K.; Shirakawa, J.; Kinoshita, H.; Ito, K.; et al. Non-invasive measurement of skin autofluorescence to evaluate diabetic complications. J. Clin. Biochem. Nutr. 2016, 58, 135–140. [Google Scholar] [CrossRef]
  49. Hause, F.; Schlote, D.; Simm, A.; Hoffmann, K.; Santos, A.N. Accumulation of glycated proteins suggesting premature ageing in lamin B receptor deficient mice. Biogerontology 2018, 19, 95–100. [Google Scholar] [CrossRef]
  50. Nowotny, K.; Castro, J.P.; Hugo, M.; Braune, S.; Weber, D.; Pignitter, M.; Somoza, V.; Bornhorst, J.; Schwerdtle, T.; Grune, T. Oxidants produced by methylglyoxal-modified collagen trigger ER stress and apoptosis in skin fibroblasts. Free. Radic. Biol. Med. 2018, 120, 102–113. [Google Scholar] [CrossRef]
  51. Nicolas, C.; Jaisson, S.; Gorisse, L.; Tessier, F.J.; Niquet-Léridon, C.; Jacolot, P.; Pietrement, C.; Gillery, P. Carbamylation and glycation compete for collagen molecular aging in vivo. Sci. Rep. 2019, 9, 18291. [Google Scholar] [CrossRef] [PubMed]
  52. Kang, Y.; Zheng, C.; Ye, J.; Song, F.; Wang, X.; Liu, Y.; Tian, M.; Dong, J.; Lu, S. Effects of advanced glycation end products on neutrophil migration and aggregation in diabetic wounds. Aging 2021, 13, 12143–12159. [Google Scholar] [CrossRef] [PubMed]
  53. Hiramoto, K.; Imai, M.; Tanaka, S.; Ooi, K. Changes in the AGE/Macrophage/TNF-α Pathway Affect Skin Dryness during KK-Ay/Tajcl Mice Aging. Life 2023, 13, 1339. [Google Scholar] [CrossRef] [PubMed]
  54. Li, W.-Z.; Liu, X.-X.; Shi, Y.-J.; Wang, X.-R.; Li, L.; Tai, M.-L.; Yi, F. Unveiling the mechanism of high sugar diet induced advanced glycosylation end products damage skin structure via extracellular matrix–receptor interaction pathway. J. Cosmet. Dermatol. 2024, 23, 2496–2508. [Google Scholar] [CrossRef]
  55. Odani, H.; Iijima, K.; Nakata, M.; Miyata, S.; Kusunoki, H.; Yasuda, Y.; Hiki, Y.; Irie, S.; Maeda, K.; Fujimoto, D. Identification of Nω-Carboxymethylarginine, a New Advanced Glycation Endproduct in Serum Proteins of Diabetic Patients: Possibility of a New Marker of Aging and Diabetes. Biochem. Biophys. Res. Commun. 2001, 285, 1232–1236. [Google Scholar] [CrossRef]
  56. Sakai, S.; Kikuchi, K.; Satoh, J.; Tagami, H.; Inoue, S. Functional properties of the stratum corneum in patients with diabetes mellitus: Similarities to senile xerosis. Br. J. Dermatol. 2005, 153, 319–323. [Google Scholar] [CrossRef]
  57. Ohshima, H.; Oyobikawa, M.; Tada, A.; Maeda, T.; Takiwaki, H.; Itoh, M.; Kanto, H. Melanin and facial skin fluorescence as markers of yellowish discoloration with aging. Skin. Res. Technol. 2009, 15, 496–502. [Google Scholar] [CrossRef]
  58. Momma, H.; Niu, K.; Kobayashi, Y.; Guan, L.; Sato, M.; Guo, H.; Chujo, M.; Otomo, A.; Yufei, C.; Tadaura, H.; et al. Skin advanced glycation end product accumulation and muscle strength among adult men. Eur. J. Appl. Physiol. 2011, 111, 1545–1552. [Google Scholar] [CrossRef]
  59. Cleary, P.A.; Braffett, B.H.; Orchard, T.; Lyons, T.J.; Maynard, J.; Cowie, C.; Gubitosi-Klug, R.A.; Way, J.; Anderson, K.; Barnie, A.; et al. Clinical and technical factors associated with skin intrinsic fluorescence in subjects with type 1 diabetes from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Technol. Ther. 2013, 15, 466–474. [Google Scholar] [CrossRef]
  60. Mamalis, A.; Fiadorchanka, N.; Adams, L.; Serravallo, M.; Heilman, E.; Siegel, D.; Brody, N.; Jagdeo, J. An immunohistochemical panel to assess ultraviolet radiation-associated oxidative skin injury. J. Drugs Dermatol. 2014, 13, 574–578. [Google Scholar]
  61. Pepe, D.; Elliott, C.G.; Forbes, T.L.; Hamilton, D.W. Detection of galectin-3 and localization of advanced glycation end products (AGE) in human chronic skin wounds. Histol. Histopathol. 2014, 29, 251–258. [Google Scholar] [CrossRef]
  62. Spauwen, P.J.; van Eupen, M.G.; Köhler, S.; Stehouwer, C.D.; Verhey, F.R.; van der Kallen, C.J.; Sep, S.J.; Koster, A.; Schaper, N.C.; Dagnelie, P.C.; et al. Associations of advanced glycation end-products with cognitive functions in individuals with and without type 2 diabetes: The maastricht study. J. Clin. Endocrinol. Metab. 2015, 100, 951–960. [Google Scholar] [CrossRef]
  63. Chen, J.; van der Duin, D.; Campos-Obando, N.; Ikram, M.A.; Nijsten, T.E.C.; Uitterlinden, A.G.; Zillikens, M.C. Serum 25-hydroxyvitamin D(3) is associated with advanced glycation end products (AGEs) measured as skin autofluorescence: The Rotterdam Study. Eur. J. Epidemiol. 2019, 34, 67–77. [Google Scholar] [CrossRef]
  64. Shirakami, T.; Yamanaka, M.; Fujihara, J.; Matsuoka, Y.; Gohto, Y.; Obana, A.; Tanito, M. Advanced Glycation End Product Accumulation in Subjects with Open-Angle Glaucoma with and without Exfoliation. Antioxidants 2020, 9, 755. [Google Scholar] [CrossRef] [PubMed]
  65. Yoshinaga, E.; Kawada, A.; Ono, K.; Fujimoto, E.; Wachi, H.; Harumiya, S.; Nagai, R.; Tajima, S. N(ε)-(carboxymethyl)lysine modification of elastin alters its biological properties: Implications for the accumulation of abnormal elastic fibers in actinic elastosis. J. Invest. Dermatol. 2012, 132, 315–323. [Google Scholar] [CrossRef]
  66. Mooldijk, S.S.; Lu, T.; Waqas, K.; Chen, J.; Vernooij, M.W.; Ikram, M.K.; Zillikens, M.C.; Ikram, M.A. Skin autofluorescence, reflecting accumulation of advanced glycation end products, and the risk of dementia in a population-based cohort. Sci. Rep. 2024, 14, 1256. [Google Scholar] [CrossRef] [PubMed]
  67. Hattangadi, S.M.; Lodish, H.F. Regulation of erythrocyte lifespan: Do reactive oxygen species set the clock? J. Clin. Investig. 2007, 117, 2075–2077. [Google Scholar] [CrossRef] [PubMed]
  68. Iacobini, C.; Menini, S.; Oddi, G.; Ricci, C.; Amadio, L.; Pricci, F.; Olivieri, A.; Sorcini, M.; Di Mario, U.; Pesce, C.; et al. Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: Evidence for a protective role of galectin-3 as an AGE receptor. Faseb J. 2004, 18, 1773–1775. [Google Scholar] [CrossRef]
  69. Hayashi, C.M.; Nagai, R.; Miyazaki, K.; Hayase, F.; Araki, T.; Ono, T.; Horiuchi, S. Conversion of Amadori products of the Maillard reaction to N(ε)-(carboxymethyl) lysine by short-term heating: Possible detection of artifacts by immunohistochemistry. Lab. Investig. 2002, 82, 795–807. [Google Scholar] [CrossRef]
  70. Péterszegi, G.; Andrès, E.; Molinari, J.; Ravelojaona, V.; Robert, L. Effect of cellular aging on collagen biosynthesis: I. Methodological considerations and pharmacological applications. Arch. Gerontol. Geriatr. 2008, 47, 356–367. [Google Scholar] [CrossRef]
  71. Pageon, H.; Técher, M.P.; Asselineau, D. Reconstructed skin modified by glycation of the dermal equivalent as a model for skin aging and its potential use to evaluate anti-glycation molecules. Exp. Gerontol. 2008, 43, 584–588. [Google Scholar] [CrossRef]
  72. Ravelojaona, V.; Robert, A.M.; Robert, L. Expression of senescence-associated beta-galactosidase (SA-beta-Gal) by human skin fibroblasts, effect of advanced glycation end-products and fucose or rhamnose-rich polysaccharides. Arch. Gerontol. Geriatr. 2009, 48, 151–154. [Google Scholar] [CrossRef] [PubMed]
  73. Kim, J.H.; Hong, C.O.; Koo, Y.C.; Choi, H.D.; Lee, K.W. Anti-glycation effect of gold nanoparticles on collagen. Biol. Pharm. Bull. 2012, 35, 260–264. [Google Scholar] [CrossRef]
  74. Pageon, H.; Zucchi, H.; Rousset, F.; Monnier, V.M.; Asselineau, D. Skin aging by glycation: Lessons from the reconstructed skin model. Clin. Chem. Lab. Med. 2014, 52, 169–174. [Google Scholar] [CrossRef] [PubMed]
  75. Danoux, L.; Mine, S.; Abdul-Malak, N.; Henry, F.; Jeanmaire, C.; Freis, O.; Pauly, G.; Cittadini, L.; André-Frei, V.; Rathjens, A. How to help the skin cope with glycoxidation. Clin. Chem. Lab. Med. 2014, 52, 175–182. [Google Scholar] [CrossRef] [PubMed]
  76. Shin, S.; Lee, J.A.; Kim, M.; Kum, H.; Jung, E.; Park, D. Anti-glycation activities of phenolic constituents from Silybum marianum (Milk Thistle) flower in vitro and on human explants. Molecules 2015, 20, 3549–3564. [Google Scholar] [CrossRef]
  77. Shin, S.; Son, D.; Kim, M.; Lee, S.; Roh, K.B.; Ryu, D.; Lee, J.; Jung, E.; Park, D. Ameliorating Effect of Akebia quinata Fruit Extracts on Skin Aging Induced by Advanced Glycation End Products. Nutrients 2015, 7, 9337–9352. [Google Scholar] [CrossRef]
  78. Pennacchi, P.C.; de Almeida, M.E.; Gomes, O.L.; Faião-Flores, F.; de Araújo Crepaldi, M.C.; Dos Santos, M.F.; de Moraes Barros, S.B.; Maria-Engler, S.S. Glycated Reconstructed Human Skin as a Platform to Study the Pathogenesis of Skin Aging. Tissue Eng. Part. A 2015, 21, 2417–2425. [Google Scholar] [CrossRef]
  79. Han, A.R.; Nam, M.H.; Lee, K.W. Plantamajoside Inhibits UVB and Advanced Glycation End Products-Induced MMP-1 Expression by Suppressing the MAPK and NF-kappaB Pathways in HaCaT Cells. Photochem. Photobiol. 2016, 92, 708–719. [Google Scholar] [CrossRef]
  80. Ou, J.; Huang, J.; Wang, M.; Ou, S. Effect of rosmarinic acid and carnosic acid on AGEs formation in vitro. Food Chem. 2017, 221, 1057–1061. [Google Scholar] [CrossRef]
  81. Fernandes, M.F.; Conegundes, J.L.M.; Pinto, N.C.C.; de Oliveira, L.G.; de Aguiar, J.A.K.; Souza-Fagundes, E.M.; Scio, E. Cecropia pachystachya Leaves Present Potential to Be Used as New Ingredient for Antiaging Dermocosmetics. Evid. Based Complement. Alternat Med. 2019, 2019, 8263934. [Google Scholar] [CrossRef]
  82. Orfanoudaki, M.; Hartmann, A.; Alilou, M.; Gelbrich, T.; Planchenault, P.; Derbré, S.; Schinkovitz, A.; Richomme, P.; Hensel, A.; Ganzera, M. Absolute Configuration of Mycosporine-Like Amino Acids, Their Wound Healing Properties and In Vitro Anti-Aging Effects. Mar. Drugs 2019, 18, 35. [Google Scholar] [CrossRef] [PubMed]
  83. Drouet, S.; Leclerc, E.A.; Garros, L.; Tungmunnithum, D.; Kabra, A.; Abbasi, B.H.; Lainé, É.; Hano, C. A Green Ultrasound-Assisted Extraction Optimization of the Natural Antioxidant and Anti-Aging Flavonolignans from Milk Thistle Silybum marianum (L.) Gaertn. Fruits for Cosmetic Applications. Antioxidants 2019, 8, 304. [Google Scholar] [CrossRef] [PubMed]
  84. Li, H.; DaSilva, N.A.; Liu, W.; Xu, J.; Dombi, G.W.; Dain, J.A.; Li, D.; Chamcheu, J.C.; Seeram, N.P.; Ma, H. Thymocid(®), a Standardized Black Cumin (Nigella sativa) Seed Extract, Modulates Collagen Cross-Linking, Collagenase and Elastase Activities, and Melanogenesis in Murine B16F10 Melanoma Cells. Nutrients 2020, 12, 2146. [Google Scholar] [CrossRef]
  85. Freitas, L.d.; Valli, M.; Dametto, A.C.; Pennacchi, P.C.; Andricopulo, A.D.; Maria-Engler, S.S.; Bolzani, V.S. Advanced Glycation End Product Inhibition by Alkaloids from Ocotea paranapiacabensis for the Prevention of Skin Aging. J. Nat. Prod. 2020, 83, 649–656. [Google Scholar] [CrossRef] [PubMed]
  86. Spagnuolo, L.; Della Posta, S.; Fanali, C.; Dugo, L.; De Gara, L. Antioxidant and Antiglycation Effects of Polyphenol Compounds Extracted from Hazelnut Skin on Advanced Glycation End-Products (AGEs) Formation. Antioxidants 2021, 10, 424. [Google Scholar] [CrossRef]
  87. Waditee-Sirisattha, R.; Kageyama, H. Protective effects of mycosporine-like amino acid-containing emulsions on UV-treated mouse ear tissue from the viewpoints of antioxidation and antiglycation. J. Photochem. Photobiol. B. 2021, 223, 112296. [Google Scholar] [CrossRef]
  88. Lin, H.; Lin, T.Y.; Lin, J.A.; Cheng, K.C.; Santoso, S.P.; Chou, C.H.; Hsieh, C.W. Effect of Pholiota nameko Polysaccharides Inhibiting Methylglyoxal-Induced Glycation Damage In Vitro. Antioxidants 2021, 10, 1589. [Google Scholar] [CrossRef]
  89. Shin, S.; Lee, J.; Yoon, S.H.; Park, D.; Hwang, J.S.; Jung, E. Anti-glycation activities of methyl gallate in vitro and in human explants. J. Cosmet. Dermatol. 2022, 21, 2602–2609. [Google Scholar] [CrossRef]
  90. Yoon, S.; Kim, M.; Shin, S.; Woo, J.; Son, D.; Ryu, D.; Yoo, J.; Park, D.; Jung, E. Effect of Cirsium japonicum Flower Extract on Skin Aging Induced by Glycation. Molecules 2022, 27, 2093. [Google Scholar] [CrossRef]
  91. Imai, Y.; Nakashima, Y.; Kanno, T. Inhibitory Effects of Parachlorella Beijerinckii Extracts on the Formation of Advanced Glycation End Products and Glycative Stress-Induced Inflammation in an In Vitro Skin Dermis-Like Model. Evid.-Based Complement. Altern. Med. 2022, 2022, 8789903. [Google Scholar] [CrossRef] [PubMed]
  92. Alhadid, A.; Bustanji, Y.; Harb, A.; Al-Hiari, Y.; Abdalla, S. Vanillic Acid Inhibited the Induced Glycation Using In Vitro and In Vivo Models. Evid. Based Complement. Alternat Med. 2022, 2022, 7119256. [Google Scholar] [CrossRef] [PubMed]
  93. Chang, H.; Johnson, E.; Khoo, C.; Wang, W.; Gu, L. Cranberry Juice Polyphenols Inhibited the Formation of Advanced Glycation End Products in Collagens, Inhibited Advanced Glycation End Product-Induced Collagen Crosslinking, and Cleaved the Formed Crosslinks. J. Agric. Food Chem. 2022, 70, 15560–15569. [Google Scholar] [CrossRef] [PubMed]
  94. Spagnuolo, L.; Della Posta, S.; Fanali, C.; Dugo, L.; De Gara, L. Chemical Composition of Hazelnut Skin Food Waste and Protective Role against Advanced Glycation End-Products (AGEs) Damage in THP-1-Derived Macrophages. Molecules 2023, 28, 2680. [Google Scholar] [CrossRef]
  95. Knoblich, C.; Dunckelmann, K.; Krüger, A.; Küper, T.; Blatt, T.; Weise, J.M. N-acetyl-L-hydroxyproline—A potent skin anti-ageing active preventing advanced glycation end-product formation in vitro and ex vivo. Int. J. Cosmet. Sci. 2024, 46, 297–306. [Google Scholar] [CrossRef]
  96. Sultana, R.; Parveen, A.; Kang, M.-C.; Hong, S.-M.; Kim, S.Y. Glyoxal-derived advanced glycation end products (GO-AGEs) with UVB critically induce skin inflammaging: In vitro and in silico approaches. Sci. Rep. 2024, 14, 1843. [Google Scholar] [CrossRef]
  97. Yokota, M.; Tokudome, Y. The Effect of Glycation on Epidermal Lipid Content, Its Metabolism and Change in Barrier Function. Skin. Pharmacol. Physiol. 2016, 29, 231–242. [Google Scholar] [CrossRef]
  98. Pageon, H.; Asselineau, D. An in vitro approach to the chronological aging of skin by glycation of the collagen: The biological effect of glycation on the reconstructed skin model. Ann. N. Y. Acad. Sci. 2005, 1043, 529–532. [Google Scholar] [CrossRef]
  99. Pageon, H.; Zucchi, H.; Dai, Z.; Sell, D.R.; Strauch, C.M.; Monnier, V.M.; Asselineau, D. Biological Effects Induced by Specific Advanced Glycation End Products in the Reconstructed Skin Model of Aging. BioResearch Open Access 2015, 4, 54–64. [Google Scholar] [CrossRef]
  100. Robert, L.; Molinari, J.; Ravelojaona, V.; Andrès, E.; Robert, A.M. Age- and passage-dependent upregulation of fibroblast elastase-type endopeptidase activity. Role of advanced glycation endproducts, inhibition by fucose- and rhamnose-rich oligosaccharides. Arch. Gerontol. Geriatr. 2010, 50, 327–331. [Google Scholar] [CrossRef]
  101. Cadau, S.; Leoty-okombi, S.; Pain, S.; Béchetoille, N.; Andre-frei, V.; Berthod, F. In vitro glycation of an endothelialized and innervated tissue-engineered skin to screen anti-AGE molecules. Biomaterials 2015, 51, 216–225. [Google Scholar] [CrossRef]
  102. Balansin Rigon, R.; Kaessmeyer, S.; Wolff, C.; Hausmann, C.; Zhang, N.; Sochorová, M.; Kováčik, A.; Haag, R.; Vávrová, K.; Ulrich, M.; et al. Ultrastructural and Molecular Analysis of Ribose-Induced Glycated Reconstructed Human Skin. Int. J. Mol. Sci. 2018, 19, 3521. [Google Scholar] [CrossRef]
  103. Li, X.; Yang, K.; Gao, S.; Zhao, J.; Liu, G.; Chen, Y.; Lin, H.; Zhao, W.; Hu, Z.; Xu, N. Carnosine Stimulates Macrophage-Mediated Clearance of Senescent Skin Cells Through Activation of the AKT2 Signaling Pathway by CD36 and RAGE. Front. Pharmacol. 2020, 11, 593832. [Google Scholar] [CrossRef] [PubMed]
  104. Lee, Y.I.; Lee, S.G.; Jung, I.; Suk, J.; Lee, M.H.; Kim, D.U.; Lee, J.H. Effect of a Topical Collagen Tripeptide on Antiaging and Inhibition of Glycation of the Skin: A Pilot Study. Int. J. Mol. Sci. 2022, 23, 1101. [Google Scholar] [CrossRef]
  105. Lyu, J.L.; Liu, Y.J.; Wen, K.C.; Chiu, C.Y.; Lin, Y.H.; Chiang, H.M. Protective Effect of Djulis (Chenopodium formosanum) Extract against UV- and AGEs-Induced Skin Aging via Alleviating Oxidative Stress and Collagen Degradation. Molecules 2022, 27, 2332. [Google Scholar] [CrossRef] [PubMed]
  106. Barua, S.; Jiang, L.I.; Kononov, T.; Zahr, A.S. A case study investigating the short-term efficacy and tolerability of a daily serum composed from a unique sunflower sprout extract. J. Cosmet. Dermatol. 2022, 21, 4410–4421. [Google Scholar] [CrossRef]
  107. Markiewicz, E.; Jerome, J.; Mammone, T.; Idowu, O.C. Anti-Glycation and Anti-Aging Properties of Resveratrol Derivatives in the in-vitro 3D Models of Human Skin. Clin. Cosmet. Investig. Dermatol. 2022, 15, 911–927. [Google Scholar] [CrossRef] [PubMed]
  108. Ceccacci, S.; Lucia, A.; Tortora, A.; Colantuono, A.; Carotenuto, G.; Tito, A.; Monti, M.C. Jasminum sambac Cell Extract as Antioxidant Booster against Skin Aging. Antioxidants 2022, 11, 2409. [Google Scholar] [CrossRef]
  109. Wattanapitayakul, S.K.; Jarisarapurin, W.; Kunchana, K.; Setthawong, V.; Chularojmontri, L. Unripe Carica papaya Fresh Fruit Extract Protects against Methylglyoxal-Mediated Aging in Human Dermal Skin Fibroblasts. Prev. Nutr. Food Sci. 2023, 28, 235–245. [Google Scholar] [CrossRef]
  110. Bai, D.; Wang, Z.; Xie, L.; Lu, B.; Wang, M.; Zhang, J. Topical Transdermal Administration of Supramolecular Self-Assembled Carnosine for Anti-Melanin and Anti-Aging. Adv. Healthc. Mater. 2024, 13, e2401960. [Google Scholar] [CrossRef]
  111. Augello, F.R.; Lombardi, F.; Ciafarone, A.; Ciummo, V.; Altamura, S.; Giuliani, M.; Cinque, B.; Palumbo, P. Efficacy of an Innovative Poly-Component Formulation in Counteracting Human Dermal Fibroblast Aging by Influencing Oxidative and Inflammatory Pathways. Biomedicines 2024, 12, 2030. [Google Scholar] [CrossRef] [PubMed]
  112. Pageon, H. Reaction of glycation and human skin: The effects on the skin and its components, reconstructed skin as a model. Pathologie Biologie 2010, 58, 226–231. [Google Scholar] [CrossRef]
  113. Narda, M.; Peno-Mazzarino, L.; Krutmann, J.; Trullas, C.; Granger, C. Novel Facial Cream Containing Carnosine Inhibits Formation of Advanced Glycation End-Products in Human Skin. Ski. Pharmacol. Physiol. 2018, 31, 324–331. [Google Scholar] [CrossRef] [PubMed]
  114. Havas, F.; Krispin, S.; Cohen, M.; Loing, E.; Farge, M.; Suere, T.; Attia-Vigneau, J. A Dunaliella salina Extract Counteracts Skin Aging under Intense Solar Irradiation Thanks to Its Antiglycation and Anti-Inflammatory Properties. Mar. Drugs 2022, 20, 104. [Google Scholar] [CrossRef]
  115. De Decker, I.; Notebaert, M.; Speeckaert, M.M.; Claes, K.E.Y.; Blondeel, P.; Van Aken, E.; Van Dorpe, J.; De Somer, F.; Heintz, M.; Monstrey, S.; et al. Enzymatic Deglycation of Damaged Skin by Means of Combined Treatment of Fructosamine-3-Kinase and Fructosyl-Amino Acid Oxidase. Int. J. Mol. Sci. 2023, 24, 8981. [Google Scholar] [CrossRef] [PubMed]
  116. Tohgasaki, T.; Nishizawa, S.; Kondo, S.; Ishiwatari, S.; Sakurai, T. Long Hanging Structure of Collagen VII Connects the Elastic Fibers and the Basement Membrane in Young Skin Tissue. J. Histochem. Cytochem. 2022, 70, 751–757. [Google Scholar] [CrossRef]
  117. Odetti, P.R.; Borgoglio, A.; De Pascale, A.; Rolandi, R.; Adezati, L. Prevention of diabetes-increased aging effect on rat collagen-linked fluorescence by aminoguanidine and rutin. Diabetes 1990, 39, 796–801. [Google Scholar] [CrossRef] [PubMed]
  118. Taylor, A.; Lipman, R.D.; Jahngen-Hodge, J.; Palmer, V.; Smith, D.; Padhye, N.; Dallal, G.E.; Cyr, D.E.; Laxman, E.; Shepard, D.; et al. Dietary calorie restriction in the Emory mouse: Effects on lifespan, eye lens cataract prevalence and progression, levels of ascorbate, glutathione, glucose, and glycohemoglobin, tail collagen breaktime, DNA and RNA oxidation, skin integrity, fecundity, and cancer. Mech. Ageing Dev. 1995, 79, 33–57. [Google Scholar] [CrossRef]
  119. Sell, D.R. Ageing promotes the increase of early glycation Amadori product as assessed by epsilon-N-(2-furoylmethyl)-L-lysine (furosine) levels in rodent skin collagen. The relationship to dietary restriction and glycoxidation. Mech. Ageing Dev. 1997, 95, 81–99. [Google Scholar] [CrossRef]
  120. Novelli, M.; Masiello, P.; Bombara, M.; Bergamini, E. Protein glycation in the aging male Sprague-Dawley rat: Effects of antiaging diet restrictions. J. Gerontol. A Biol. Sci. Med. Sci. 1998, 53, B94–B101. [Google Scholar] [CrossRef]
  121. Yamada, S.; Ohkubo, C. The influence of frequent and excessive intake of glucose on microvascular aging in healthy mice. Microcirculation 1999, 6, 55–62. [Google Scholar] [CrossRef] [PubMed]
  122. Iqbal, M.; Probert, L.L.; Alhumadi, N.H.; Klandorf, H. Protein glycosylation and advanced glycosylated endproducts (AGEs) accumulation: An avian solution? J. Gerontol. A Biol. Sci. Med. Sci. 1999, 54, B171–B176; discussion B177–B178. [Google Scholar] [CrossRef]
  123. Song, X.; Bao, M.; Li, D.; Li, Y.M. Advanced glycation in D-galactose induced mouse aging model. Mech. Ageing Dev. 1999, 108, 239–251. [Google Scholar] [CrossRef]
  124. Lingelbach, L.B.; Mitchell, A.E.; Rucker, R.B.; McDonald, R.B. Accumulation of Advanced Glycation Endproducts in Aging Male Fischer 344 Rats during Long-Term Feeding of Various Dietary Carbohydrates. J. Nutr. 2000, 130, 1247–1255. [Google Scholar] [CrossRef] [PubMed]
  125. Klandorf, H.; Rathore, D.S.; Iqbal, M.; Shi, X.; Van Dyke, K. Accelerated tissue aging and increased oxidative stress in broiler chickens fed allopurinol. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2001, 129, 93–104. [Google Scholar] [CrossRef]
  126. Sell, D.R.; Nelson, J.F.; Monnier, V.M. Effect of chronic aminoguanidine treatment on age-related glycation, glycoxidation, and collagen cross-linking in the Fischer 344 rat. J. Gerontol. A Biol. Sci. Med. Sci. 2001, 56, B405–B411. [Google Scholar] [CrossRef] [PubMed]
  127. Rutter, K.; Sell, D.R.; Fraser, N.; Obrenovich, M.; Zito, M.; Starke-Reed, P.; Monnier, V.M. Green Tea Extract Suppresses the Age-Related Increase in Collagen Crosslinking and Fluorescent Products in C57BL/6 Mice. IJVNR 2003, 73, 453–460. [Google Scholar] [CrossRef]
  128. Sell, D.R.; Lane, M.A.; Obrenovich, M.E.; Mattison, J.A.; Handy, A.; Ingram, D.K.; Cutler, R.G.; Roth, G.S.; Monnier, V.M. The Effect of Caloric Restriction on Glycation and Glycoxidation in Skin Collagen of Nonhuman Primates. J. Gerontol. Ser. A 2003, 58, B508–B516. [Google Scholar] [CrossRef]
  129. Zhang, S.; Dong, Z.; Peng, Z.; Lu, F. Anti-aging effect of adipose-derived stem cells in a mouse model of skin aging induced by D-galactose. PLoS ONE 2014, 9, e97573. [Google Scholar] [CrossRef]
  130. Wang, H.; Wei, S.; Xue, X.; You, Y.; Ma, Q. Adipose stem cells’ antagonism in glycosylation of D-galactose-induced skin aging of nude mice and its skin recovery function. Int. J. Immunopathol. Pharmacol. 2016, 29, 376–385. [Google Scholar] [CrossRef]
  131. Dorr, B.S.; Stahl, R.S.; Hanson-Dorr, K.C.; Furcolow, C.A. Using pentosidine and hydroxyproline to predict age and sex in an avian species. Ecol. Evol. 2017, 7, 8999–9005. [Google Scholar] [CrossRef] [PubMed]
  132. Zhou, X.; Du, H.-h.; Jiang, M.; Zhou, C.; Deng, Y.; Long, X.; Zhao, X. Antioxidant Effect of Lactobacillus fermentum CQPC04-Fermented Soy Milk on D-Galactose-Induced Oxidative Aging Mice. Front. Nutr. 2021, 8, 727467. [Google Scholar] [CrossRef] [PubMed]
  133. Gu, M.J.; Lee, H.W.; Yoo, G.; Kim, D.; Choi, I.W.; Kim, Y.; Ha, S.K. Protective effect of Schizonepeta tenuifolia Briq. ethanolic extract against UVB-induced skin aging and photodamage in hairless mice. Front. Pharmacol. 2023, 14, 1176073. [Google Scholar] [CrossRef]
  134. Xie, Y.; Ye, J.; Ouyang, Y.; Gong, J.; Li, C.; Deng, Y.; Mai, Y.; Liu, Y.; Deng, W. Microneedle-Assisted Topical Delivery of Idebenone-Loaded Bioadhesive Nanoparticles Protect against UV-Induced Skin Damage. Biomedicines 2023, 11, 1649. [Google Scholar] [CrossRef] [PubMed]
  135. Yoo, J.H.; Lee, J.S.; Jang, J.H.; Jung, J.I.; Kim, E.J.; Choi, S.Y. AGEs Blocker™ (Goji Berry, Fig, and Korean Mint Mixed Extract) Inhibits Skin Aging Caused by Streptozotocin-Induced Glycation in Hairless Mice. Prev. Nutr. Food Sci. 2023, 28, 134–140. [Google Scholar] [CrossRef]
  136. Shihab, E.M.; Kadhim, H.M.; Shahooth, S.S. Dapagliflozin mitigates oxidative stress, inflammatory, and histopathological markers of aging in mice. J. Med. Life. 2024, 17, 157–163. [Google Scholar] [CrossRef]
  137. Konen, J.C.; Summerson, J.H.; Kirk, J.K. Measurement feasability of advanced glycated end-products from skin samples after antioxidant vitamin supplementation in patients with type 2 diabetes. J. Nutr. Health Aging. 2000, 4, 81–84. [Google Scholar]
  138. Chiu, A.E.; Chan, J.L.; Kern, D.G.; Kohler, S.; Rehmus, W.E.; Kimball, A.B. Double-blinded, placebo-controlled trial of green tea extracts in the clinical and histologic appearance of photoaging skin. Dermatol. Surg. 2005, 31, 855–860; discussion 860. [Google Scholar] [CrossRef]
  139. Draelos, Z.D.; Yatskayer, M.; Raab, S.; Oresajo, C. An evaluation of the effect of a topical product containing C-xyloside and blueberry extract on the appearance of type II diabetic skin. J. Cosmet. Dermatol. 2009, 8, 147–151. [Google Scholar] [CrossRef]
  140. Babizhayev, M.A.; Deyev, A.I.; Savel’yeva, E.L.; Lankin, V.Z.; Yegorov, Y.E. Skin beautification with oral non-hydrolized versions of carnosine and carcinine: Effective therapeutic management and cosmetic skincare solutions against oxidative glycation and free-radical production as a causal mechanism of diabetic complications and skin aging. J. Dermatolog Treat. 2012, 23, 345–384. [Google Scholar] [CrossRef]
  141. Yoshikata, R.; Myint, K.Z.Y.; Ohta, H.; Ishigaki, Y. Effects of an equol-containing supplement on advanced glycation end products, visceral fat and climacteric symptoms in postmenopausal women: A randomized controlled trial. PLoS ONE 2021, 16, e0257332. [Google Scholar] [CrossRef] [PubMed]
  142. Koizumi, S.; Okada, Y.; Miura, S.; Imai, Y.; Igase, K.; Ohyagi, Y.; Igase, M. Ingestion of a collagen peptide containing high concentrations of prolyl-hydroxyproline and hydroxyprolyl-glycine reduces advanced glycation end products levels in the skin and subcutaneous blood vessel walls: A randomized, double-blind, placebo-controlled study. Biosci. Biotechnol. Biochem. 2023, 87, 883–889. [Google Scholar] [CrossRef] [PubMed]
  143. Zhang, Q.; Cheng, D.; Wang, F. Facial assessment methods for inhibiting glycation and aging effects and the correlation between glycation and aging parameters. Sci. Rep. 2025, 15, 1935. [Google Scholar] [CrossRef] [PubMed]
  144. Guiotto, A.; Pecorelli, A.; Draelos, Z.D.; Gueniche, A.; Yatskayer, M.; Nelson, D.B. Reversing Oxinflammation Associated with Glycative Stress and Formation of Advanced Glycation End Products with a Dietary Supplement Containing Rosemary Extract. J. Clin. Aesthet. Dermatol. 2025, 18, 34–38. [Google Scholar]
  145. Papaccio, F.; Caputo, S.; Bellei, B. Focus on the Contribution of Oxidative Stress in Skin Aging. Antioxidants 2022, 11, 1121. [Google Scholar] [CrossRef]
  146. Bavkar, L.N.; Patil, R.S.; Rooge, S.B.; Nalawade, M.L.; Arvindekar, A.U. Acceleration of protein glycation by oxidative stress and comparative role of antioxidant and protein glycation inhibitor. Mol. Cell Biochem. 2019, 459, 61–71. [Google Scholar] [CrossRef]
  147. Mazumder, M.A.R.; Hongsprabhas, P. Genistein as antioxidant and antibrowning agents in vivo and in vitro: A review. Biomed. Pharmacother. 2016, 82, 379–392. [Google Scholar] [CrossRef]
  148. Geng, R.; Kang, S.G.; Huang, K.; Tong, T. Boosting the Photoaged Skin: The Potential Role of Dietary Components. Nutrients 2021, 13, 1691. [Google Scholar] [CrossRef]
  149. Umbayev, B.; Askarova, S.; Almabayeva, A.; Saliev, T.; Masoud, A.R.; Bulanin, D. Galactose-Induced Skin Aging: The Role of Oxidative Stress. Oxid. Med. Cell Longev. 2020, 2020, 7145656. [Google Scholar] [CrossRef]
  150. Chmielewski, R.; Lesiak, A. Mitigating Glycation and Oxidative Stress in Aesthetic Medicine: Hyaluronic Acid and Trehalose Synergy for Anti-AGEs Action in Skin Aging Treatment. Clin. Cosmet. Investig. Dermatol. 2024, 17, 2701–2712. [Google Scholar] [CrossRef]
  151. Draelos, Z.D. INDIVIDUAL ARTICLE: Sugar Sag: What Is Skin Glycation and How Do You Combat It? J. Drugs Dermatol. 2024, 23, S5–S10. [Google Scholar] [CrossRef] [PubMed]
  152. Almeida, J.K.A.; Brech, G.C.; Luna, N.M.S.; Iborra, R.T.; Soares-Junior, J.M.; Baracat, E.C.; Greve, J.M.D.; Alonso, A.C.; Machado-Lima, A. Advanced glycation end products consumption and the decline of functional capacity in patients with Parkinson’s disease: Cross-sectional study. Clinics 2024, 79, 100320. [Google Scholar] [CrossRef] [PubMed]
  153. Drenth, H.; Zuidema, S.U.; Krijnen, W.P.; Bautmans, I.; Smit, A.J.; van der Schans, C.; Hobbelen, H. Advanced Glycation End Products Are Associated with Physical Activity and Physical Functioning in the Older Population. J. Gerontol. A Biol. Sci. Med. Sci. 2018, 73, 1545–1551. [Google Scholar] [CrossRef]
  154. Thornalley, P.J. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch. Biochem. Biophys. 2003, 419, 31–40. [Google Scholar] [CrossRef]
  155. Harper, E.I.; Siroky, M.D.; Hilliard, T.S.; Dominique, G.M.; Hammond, C.; Liu, Y.; Yang, J.; Hubble, V.B.; Walsh, D.J.; Melander, R.J.; et al. Advanced Glycation End Products as a Potential Target for Restructuring the Ovarian Cancer Microenvironment: A Pilot Study. Int. J. Mol. Sci. 2023, 24, 9804. [Google Scholar] [CrossRef]
  156. Martinovic, D.; Tokic, D.; Usljebrka, M.; Lupi-Ferandin, S.; Cigic, L.; Vanjaka Rogosic, L.; Ercegovic, S.; Kontic, M.; Kumrić, M.; Rusic, D.; et al. The Association between the Level of Advanced Glycation End Products and Objective Skin Quality Parameters. Life 2023, 13, 256. [Google Scholar] [CrossRef] [PubMed]
  157. Fan, X.; Sell, D.R.; Zhang, J.; Nemet, I.; Theves, M.; Lu, J.; Strauch, C.; Halushka, M.K.; Monnier, V.M. Anaerobic vs aerobic pathways of carbonyl and oxidant stress in human lens and skin during aging and in diabetes: A comparative analysis. Free. Radic. Biol. Med. 2010, 49, 847–856. [Google Scholar] [CrossRef]
  158. Fu, M.X.; Wells-Knecht, K.J.; Blackledge, J.A.; Lyons, T.J.; Thorpe, S.R.; Baynes, J.W. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 1994, 43, 676–683. [Google Scholar] [CrossRef]
  159. Stamatas, G.N.; Estanislao, R.B.; Suero, M.; Rivera, Z.S.; Li, J.; Khaiat, A.; Kollias, N. Facial skin fluorescence as a marker of the skin’s response to chronic environmental insults and its dependence on age. Br. J. Dermatol. 2006, 154, 125–132. [Google Scholar] [CrossRef]
  160. Qu, D.; Venzon, D.; Murray, M.; Depauw, M. Noninvasive measurement of advanced glycation end-products in the facial skin: New data for skin aging studies. J. Cosmet. Sci. 2017, 68, 195–204. [Google Scholar]
  161. Xin, C.; Wang, Y.; Liu, M.; Zhang, B.; Yang, S. Correlation analysis between advanced glycation end products detected noninvasively and skin aging factors. J. Cosmet. Dermatol. 2021, 20, 243–248. [Google Scholar] [CrossRef] [PubMed]
  162. Hosseini, M.S.; Razavi, Z.; Ehsani, A.H.; Firooz, A.; Afazeli, S. Clinical significance of non-invasive skin autofluorescence measurement in patients with diabetes: A systematic review and meta-analysis. Eclinicalmedicine 2021, 42, 101194. [Google Scholar] [CrossRef] [PubMed]
  163. Beisswenger, P.J.; Howell, S.; Mackenzie, T.; Corstjens, H.; Muizzuddin, N.; Matsui, M.S. Two fluorescent wavelengths, 440(ex)/520(em) nm and 370(ex)/440(em) nm, reflect advanced glycation and oxidation end products in human skin without diabetes. Diabetes Technol. Ther. 2012, 14, 285–292. [Google Scholar] [CrossRef]
  164. Delanghe, J.R.; Beeckman, J.; Beerens, K.; Himpe, J.; Bostan, N.; Speeckaert, M.M.; Notebaert, M.; Huizing, M.; Van Aken, E. Topical Application of Deglycating Enzymes as an Alternative Non-Invasive Treatment for Presbyopia. Int. J. Mol. Sci. 2023, 24, 7343. [Google Scholar] [CrossRef] [PubMed]
  165. Fujino, T.; Watanabe, K.; Beppu, M.; Kikugawa, K.; Yasuda, H. Identification of oxidized protein hydrolase of human erythrocytes as acylpeptide hydrolase. Biochim. Et. Biophys. Acta BBA-Protein Struct. Mol. Enzymology 2000, 1478, 102–112. [Google Scholar] [CrossRef]
  166. Shimizu, K.; Ikegami-Kawai, M.; Takahashi, T. Increased oxidized protein hydrolase activity in serum and urine of diabetic rat models. Biol. Pharm. Bull. 2009, 32, 1632–1635. [Google Scholar] [CrossRef]
  167. Ganceviciene, R.; Liakou, A.I.; Theodoridis, A.; Makrantonaki, E.; Zouboulis, C.C. Skin anti-aging strategies. Dermatoendocrinol 2012, 4, 308–319. [Google Scholar] [CrossRef]
  168. Couturaud, V.; Le Fur, M.; Pelletier, M.; Granotier, F. Reverse skin aging signs by red light photobiomodulation. Skin. Res. Technol. 2023, 29, e13391. [Google Scholar] [CrossRef]
  169. Oh, S.; Rho, N.K.; Byun, K.A.; Yang, J.Y.; Sun, H.J.; Jang, M.; Kang, D.; Son, K.H.; Byun, K. Combined Treatment of Monopolar and Bipolar Radiofrequency Increases Skin Elasticity by Decreasing the Accumulation of Advanced Glycated End Products in Aged Animal Skin. Int. J. Mol. Sci. 2022, 23, 2993. [Google Scholar] [CrossRef]
  170. Ding, B.; Lin, C.; Liu, Q.; He, Y.; Ruganzu, J.B.; Jin, H.; Peng, X.; Ji, S.; Ma, Y.; Yang, W. Tanshinone IIA attenuates neuroinflammation via inhibiting RAGE/NF-κB signaling pathway in vivo and in vitro. J. Neuroinflammation 2020, 17, 302. [Google Scholar] [CrossRef]
  171. Hudson, B.I.; Lippman, M.E. Targeting RAGE Signaling in Inflammatory Disease. Annu. Rev. Med. 2018, 69, 349–364. [Google Scholar] [CrossRef] [PubMed]
  172. Hoang, H.T.; Moon, J.-Y.; Lee, Y.-C. Natural Antioxidants from Plant Extracts in Skincare Cosmetics: Recent Applications, Challenges and Perspectives. Cosmetics 2021, 8, 106. [Google Scholar] [CrossRef]
  173. Boo, Y.C. Natural Nrf2 Modulators for Skin Protection. Antioxidants 2020, 9, 812. [Google Scholar] [CrossRef] [PubMed]
  174. Hong, G.W.; Wan, J.; Yoon, S.E.; Wong, S.; Yi, K.H. Conditions to Consider When Choosing Fillers. J. Cosmet. Dermatol. 2025, 24, e70075. [Google Scholar] [CrossRef]
  175. Rho, N.K.; Kim, H.S.; Kim, S.Y.; Lee, W. Injectable Skin Boosters in Aging Skin Rejuvenation: A Current Overview. Arch. Plast. Surg. 2024, 51, 528–541. [Google Scholar] [CrossRef]
  176. Han, J.; Sun, Y.; Wu, T.; Hou, X.; Zheng, S.; Zhang, H.; Lin, T.; Liu, H.; Sun, T. Echinacoside-Zinc Nanomaterial Inhibits Skin Glycation by Suppressing the Transcriptional Activation of the Receptor for Advanced Glycation End-Products. ACS Nano. 2023, 17, 14123–14135. [Google Scholar] [CrossRef]
Figure 1. Causative factors for glycation stress-associated skin aging and interventions using synthetic and natural agents with antiglycation or antioxidant activity. Sharp arrows (↓) indicate stimulation. Plus and minus signs in parentheses indicate increases and decreases, respectively. Interventions are indicated with a blue background.
Figure 1. Causative factors for glycation stress-associated skin aging and interventions using synthetic and natural agents with antiglycation or antioxidant activity. Sharp arrows (↓) indicate stimulation. Plus and minus signs in parentheses indicate increases and decreases, respectively. Interventions are indicated with a blue background.
Antioxidants 14 00498 g001
Figure 2. Potential therapeutic targets and treatment strategies against glycation-induced skin aging. Sharp (↓) and blunt (⊥) arrows indicate stimulation and suppression, respectively.
Figure 2. Potential therapeutic targets and treatment strategies against glycation-induced skin aging. Sharp (↓) and blunt (⊥) arrows indicate stimulation and suppression, respectively.
Antioxidants 14 00498 g002
Table 1. Animal studies on the detection of advanced glycation end-products (AGEs) in the skin and observation of glycation-induced skin aging.
Table 1. Animal studies on the detection of advanced glycation end-products (AGEs) in the skin and observation of glycation-induced skin aging.
ModelGlycation InducerFindingsReferences
Sprague–Dawley ratsDiabetes induced by streptozotocin (70 mg kg−1, i.p.)1. Increased glycated plasma proteins, glycated hemoglobin (Hb), and fructosamine.
2. The AGE levels of liver histones and skin collagen increased with the duration of diabetes and animal age.
Gugliucci and Bendayan, 1995 [42]
Sprague–Dawley ratsGlucose, sucrose, or fructose in drinking water (250 g L−1)1. Blood glycated Hb levels and urine lipid peroxidation products were higher in fructose-fed rats.
2. Insoluble collagen and collagen-bound fluorescence were higher in fructose-fed rats.
Levi and Werman, 1998 [43]
db/db(+/+) miceHigh-AGE diets1. Increased the levels of AGEs, such as Nε-(carboxymethyl)lysine (CML) and methylglyoxal derivatives, of skin proteins and collagen in diabetic mice.
2. Delayed skin wound closure in diabetic mice.
Peppa et al., 2003 [44]
CD1 miceCML-collagen injection1. Induced fibroblast apoptosis mediated by the receptor for advanced glycation end-products (RAGE) and caspases 3, 8, and 9.
2. Enhanced mRNA levels of pro-apoptotic genes.
Alikhani et al., 2005 [45]
Fatty OLETF rats and control LETO ratsLong-standing hyperglycemia1. Fatty OLETF rats with diabetes or impaired glucose tolerance had higher serum AGE levels and epidermal RAGE levels.
2. Impaired skin barrier functions, including transdermal permeability and antimicrobial barriers.
Park et al., 2011 [46]
Ansell’s mole-rats (Fukomys anselli)Age (1–19 years) and breeding status1. Glucosepane, pentosidine, CML, and Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1) in insoluble skin collagen increased with age.
2. Glucosepane and CML were higher in breeders versus nonbreeders.
3. The pentosidine formation rate was lower in mole-rats than in other short-lived rodents.
Dammann et al., 2012 [47]
C57BL6/J miceAge1. Argpyrimidine and pentosidine, but not protein carbonyls, increased in the skin of old mice.Nowotny and Grune, 2014 [24]
ddY miceDiabetes induced by streptozotocin (150 mg kg−1, abdominal injection)1. Increased blood glucose and fluorescent AGE levels in the auricle and decreased body weight.Yamanaka et al., 2016 [48]
Lamin B receptor-deficient icJ/icJ mice (NMRI background)Progeria (premature aging symptoms)1. Pentosidine and argpyrimidine, but not CML, increased in the heart and liver (not skin) of icJ/icJ mice.Hause et al., 2018 [49]
C57BL/6J miceAge1. Increased the levels of methylglyoxal-modified AGEs (argpyrimidine and MG-H1) in brain tissue and collagen.Nowotny et al., 2018 [50]
ddY mice 20 weeks1. The skin level of Nω-(carboxymethyl)arginine (CMA) was higher than CML, Nε-(carboxyethyl)lysine (CEL), and MG-H1.Kinoshita et al., 2019 [25]
db/db [C57Bl/KsJ-db/db] mice and the corresponding controls (db/+)Chronic kidney disease by nephrectomy or cyanate-supplemented water 1. Diabetes increased glycation products (furosine and CML), whereas chronic kidney disease increased carbamylation products (homocitrulline) in the skin and aorta and in skin type I collagen.
2. Carbamylation of proteins precedes their glycation, with the former competitively inhibiting the latter protein modification.
Nicolas et al., 2019 [51]
Sprague–Dawley ratsDiabetes induced by streptozotocin (50 mg kg−1, i.p.)1. Full-thickness excisional wounds increased AGE levels, interleukin (IL) 8 receptor A, leukotriene (LT) B4, and myeloperoxidase (MPO) in the skin wound edges more highly in the diabetic group.Kang et al., 2021 [52]
KK-Ay/TaJcl mice (C57BL/6N background) and control C57BL/6j miceAges (10, 27, 40, and 50 weeks)1. The body weight, blood glucose, skin thickness, transepidermal water loss (TEWL), AGE levels, and expression of RAGE, prostaglandin (PG) E2, tumor necrosis factor (TNF)-α, monocyte chemoattractant protein (MCP)-1, and C-C chemokine receptor (CCR) 2 were higher and the skin conductance and collagen expression were lower in the test groups compared to the age-matched control groups.
2. The age-dependent changes in these parameters were greater in the test groups than in the age-matched control groups.
Hiramoto et al., 2023 [53]
C57BL/6J miceHigh-sugar feed1. Changed toward a redder, yellower, and darker skin color.
2. Increased sebum secretion and lowered TEWL.
3. Increased skin AGE levels and decreased the expression of collagen type I, fibronectin 1, laminin-5, and tenascin C.
Li et al., 2024 [54]
Table 2. Clinical studies on the detection of AGEs in the skin and observation of glycation-mediated skin aging.
Table 2. Clinical studies on the detection of AGEs in the skin and observation of glycation-mediated skin aging.
ModelFactorsFindingsReferences
Plasma samples from 30 living human subjectsDiabetesCMA level of serum proteins was elevated in the diabetic group compared to the age-matched control group.Odani et al., 2001 [55]
49 Japanese patients with diabetesDiabetes 1. The high-frequency conductance (skin hydration) and skin surface lipid levels were lower in the group with high fasting plasma glucose (>110 mg dL−1).
2. The TEWL was slightly reduced in the group with high HbA1c levels (>5.8%).
Sakai et al., 2005 [56]
40 healthy Japanese womenAge1. Cheek skin yellowness (b* value) and the AGE index, but not the melanin index, increased with age.
2. The b* value was correlated with the AGE index or the melanin index.
Ohshima et al., 2009 [57]
Group I (232 men) and group II (138 men) among 1263 participants enrolled in annual examinationsAge1. Skin autofluorescence increased with age in group I and group II.
2. Participants with higher skin autofluorescence had lower grip strength (group I) and leg extension power (group II).
Momma et al., 2011 [58]
1441 human subjects with type I diabetes (726 with no retinopathy and 715 with nonproliferative retinopathy)Diabetes1. Skin autofluorescence in the log scale was correlated with mean HbA1c over time, age, smoking, skin tone, renal damage, and locational latitude.Cleary et al., 2013 [59]
Five patient-matched skin biopsy specimens from chronic solar ultraviolet (UV) radiation-exposed and protected skin UV exposure1. Protein damage (e.g., AGEs) was higher in the UV-exposed skin.
2. DNA damage (e.g., 8-hydroxy deoxyguanosine) was higher in the UV-exposed skin.
3. Lipid peroxidation (e.g., 4-hydroxynonenal) was higher in the UV-exposed skin.
Mamalis et al., 2014 [60]
16 human subjects with diabetes (13 with type II diabetes, one with type I diabetes, and 2 without diabetes)Wound1. Expression of galectin-3, a potential receptor for AGEs, was reduced at the wound edge and in the wound bed where the AGE level was increased. Pepe et al., 2014 [61]
A population-based cohort study involving 215 participants with type II diabetesDiabetes1. Higher skin autofluorescence levels were associated with delayed word recall and response inhibition.
2. Higher plasma levels of pentosidine, not CML or CEL, were associated with worse global cognitive functioning.
3. Associations did not differ between individuals with and without diabetes.
Spauwen et al., 2015 [62]
A total of 168 human subjects, including 82 subjects with type 2 diabetesDiabetes1. The autofluorescence intensity of fingertip skin and serum MG-H1, but not HbA1c, increased with the number of varied diabetic complications.Yamanaka et al., 2016 [48]
A population-based prospective cohort study involving 2388 human subjectsDiabetes1. Skin autofluorescence was higher in the diabetic group than in the non-diabetic group.
2. Serum 25-hydroxyvitamin D3 concentration was inversely associated with skin autofluorescence.
Chen et al., 2019 [63]
576 Japanese patients with primary open-angle glaucoma, exfoliation glaucoma, and non-glaucomatous controlsGlaucoma1. AGE level (measured by fingertip skin autofluorescence) was higher in the exfoliation glaucoma group than in the primary open-angle glaucoma or control group.
2. Male sex, exfoliation glaucoma, and diabetes, but not age, visual acuity, intraocular pressure, glaucoma medications, lens status, and systemic hypertension, were associated with higher AGE levels.
Shirakami et al., 2020 [64]
2 healthy volunteersUV exposure1. Skin CML was increased by UV irradiation.
2. The CML level was higher in the paraffin-embedded skin specimens from sun-exposed areas than sun-protected areas of human subjects, and the increase was age-dependent.
Yoshinaga et al., 2012 [65]
Table 3. In vitro studies on the glycation of protein substrates and their inhibition by various materials.
Table 3. In vitro studies on the glycation of protein substrates and their inhibition by various materials.
Protein SubstratesGlycating AgentsMedia and AdditivesReaction ConditionsMeasurementsTest MaterialsPositive ControlsReferences
Human serum albuminGlucose (1.6 M)Na-P buffer (50 mM, pH 7.2), 2 mM diethylenetriaminepentaacetic acid (DTPA)37 °C, 7 daysColorimetry with nitroblue tetrazolium (NBT) reaction.NaBH4,
DTPA
Aminoguanidine (AGD)Hayashi et al., 2002 [69]
Bovine serum albumin (BSA) (0.149 mM)Glucose (11 mM)Physiological saline, 10 mM FeCl2 37 °C, 4 weeksSpectrophotometryFucose- or rhamnose-rich oligo- and polysaccharides Péterszegi et al., 2008 [70]
Bovine collagen type IRibose (10 mM) Room temperature (RT), 1 monthFluorimetryBlueberry (Vaccinium angustifolium) extractAGDPageon et al., 2008 [71]
BSA (1%)Glucose 11 mM10 mM FeCl237 °C, 4 weeks Ravelojaona et al., 2009 [72]
α-Elastin (10 μg mL−1)Ribose (0.2 M)Phosphate-buffered saline (PBS)37 °C, 1 weekColorimetry (Elastase digestion) AGDYoshinaga et al., 2012 [65]
Collagen (3 mg mL−1)Glycolaldehyde (10 mM)1 mM HCl,
0.02% NaN3,
1 mM DTPA
37 °C, 7 daysFluorimetryGold nanoparticlesAGDKim et al., 2012 [73]
Bovine skin collagen type I (4–5 mg mL−1)Ribose (10 mM) RT, 3 weeksFluorimetry AGDPageon et al., 2014 [74]
Collagen type I (1 mg mL−1)Glucose (55 mM)Dulbecco’s phosphate-buffered saline 45 °C, 3 weeksFluorimetryManilkara extractAGD
AGD
AGD
Danoux et al., 2014 [75]
Bovine elastin (6 mg mL−1)Glycolaldehyde (10 mM)37 °C, 2 daysManilkara and Argania extracts
Albumin (6 mg mL−1)Argania extract
BSA (10 mg mL−1)Glucose (0.5 M)Phosphate buffer (0.1 M, pH 7.4), 0.02% NaN337 °C, 3 weeksFluorimetrySilybum marianum flower extract, silibininAGDShin et al., 2015 [76]
Akebia quinata fruit extractAGDShin et al., 2015 [77]
Rat tail collagen type I (at (3–4 mg mL−1) Sodium glyoxylate0.5 N acetic acid, sodium cyanoborohydride37 °C, 24 hFluorimetry AGDPennacchi et al., 2015 [78]
BSA (20 mg mL−1)Glyceraldehyde (20 mM)K-phosphate buffer (0.1 M, pH 7.4), 1 mM DTPA37 °C, 7 daysSodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) Han et al., 2016 [79]
BSA (20 mg mL−1) Glucose (20 mM), glyoxal or methylglyoxal (29 μM)PBS (0.2 M, pH 7.4), 1 mM NaN337 °C, 7 daysFluorimetryRosmarinic acid,
carnosine
Ou et al., 2017 [80]
BSA (10 mg mL−1)Fructose (1.6 M)Na-phosphate buffer (0.1 M, pH 7.4), 0.8% NaN337 °C, 7 daysFluorimetryCecropia pachystachya leaf extract,
quercetin
AGDFernandes et al., 2019 [81]
BSA (10 mg mL−1)Ribose (0.5 M)Na-phosphate buffer (50 mM, pH 7.4)37 °C for 24 hFluorimetryMycosporine-like amino acidsAGDOrfanoudaki et al., 2019 [82]
BSA (20 mg mL−1)Glucose (0.5 M)Phosphate buffer (0.1 M, pH 7.4), 0.02% NaN337 °C, 5 daysFluorimetrySilybum marianum flavonolignans Drouet et al., 2019 [83]
BSA (10 mg mL−1)Fructose (100 mM)PBS (0.2 M, pH 7.2)37 °C, 14 daysFluorimetryBlack cumin
(Nigella sativa) seed extract (rich in thymoquinone)
AGDLi et al., 2020 [84]
Bovine collagen type I (1.5 mg mL−1)Methylglyoxal (5 mM)PBS, 10 mM NaN337 °C, 30 days
BSA (1 mg mL−1)Methylglyoxal (5 mM)Phosphate buffer (pH 7.4), 150 mM NaCl37 °C, 3 daysFluorimetryAlkaloids from Ocotea paranapiacabensisAGDFreitas et al., 2020 [85]
Collagen type I (2.5 mg mL−1)Ribose (10 mM), glucose (200 mM)RT, 7 days
BSA (4 mg mL−1)Methylglyoxal (20 mM)PBS, 0.02% NaN337 °C, 7 daysFluorimetryHazelnut (Corylus avellana) skin extracts, gallic acidAGDSpagnuolo et al., 2021 [86]
Collagen, elastin, BSAGlyceraldehyde Enzyme-linked immunosorbent assay (ELISA) for AGEsMycosporine-like amino acidsAGDWaditee-Sirisattha and Kageyama, 2021 [87]
BSA (10 mg mL−1)Glucose (0.5 M)PBS, 1.5 mM phenylmethylsulfonyl fluoride (PMSF)37 °C, 2 monthsFluorimetry Kang et al., 2021 [52]
BSA (5 mg mL−1)Methylglyoxal (25 mM)Phosphate buffer (0.1 M, pH 8.0)37 °C, 24 hColorimetry with NBT reactionPholiota nameko polysaccharidesAGDLin et al., 2021 [88]
BSA (10 mg mL−1)Glucose (0.5 M)Phosphate buffer (0.1 M, pH 7.4)37 °C, 3 weeksFluorimetry for AGEs, colorimetry for protein carbonyls, and ELISA for CMLMethyl gallateAGDShin et al., 2022 [89]
BSA (10 mg mL−1)Glucose (0.5 M)Phosphate buffer (0.1 M, pH 7.4)37 °C, 28 daysFluorimetry for AGEs, colorimetry for protein carbonyls, and ELISA for CMLCirsium japonicum flower extract, apigenin, and chlorogenic acidAGDYoon et al., 2022 [90]
BSA (10 mg mL−1)Glycolaldehyde (10 mM)Phosphate buffer (0.1 M, pH 7.4), 0.02% NaN337 °C, 5 days
BSA (10 mg mL−1)Glucose (0.5 M)Phosphate buffer (0.1 M, pH 7.4)37 °C, 4 weeksFluorimetry, ELISA for CMLChlorella (Parachlorella beijerinckii) extractAGDImai et al., 2022 [91]
BSA (2 mg mL−1)Glyoxal (20 mM)37 °C, 1 week
Collagen (2 mg mL−1)Glucose (100 mM)37 °C, 4 weeks
Collagen (1 mg mL−1)Glyoxal (1 mM)37 °C, 1 week
BSA (50 mg mL−1)Glucose (50 mM)Na-phosphate buffer (0.2 M, pH 7.4), 0.02% NaN337 °C, 1 weekFluorimetryVanillic acidAGDAlhadid et al., 2022 [92]
CollagenMethylglyoxal, dehydroascorbic acidPBS (0.1 M, pH 7.4)37 °C, 7 daysFluorimetryCranberry juice (rich in polyphenols)AGD, alagebrium (ALT-711)Chang et al., 2022 [93]
BSA (4 mg mL−1)Methylglyoxal (20 mM)PBS (pH 7.4)37 °C, 168 hFluorimetry, dot blot for CML Spagnuolo et al., 2023 [94]
BSA (10.35 mg mL−1)Glucose (1 M)PBS50 °C, 6–7 daysFluorimetryN-Acetylhydroxyproline Knoblich et al., 2024 [95]
BSA (10 mg mL−1)Glyoxal (10 mM)PBS (pH 7.4), 0.2% NaN337 °C, 7 days Sultana et al., 2024 [96]
Table 4. Effects of glycation stress and various interventions on the pathological responses of cells in vitro. Upward (↑) and downward (↓) arrows indicate increases and decreases, respectively.
Table 4. Effects of glycation stress and various interventions on the pathological responses of cells in vitro. Upward (↑) and downward (↓) arrows indicate increases and decreases, respectively.
ModelGlycation InducersInduced ChangesInterventionOutcomesReferences
Reconstructed skin modelRibose (10 mM)1. CML, pentosidine (↑)
2. Integrin, collagen, procollagen, matrix metalloproteinases (MMPs) (↑)
AGD1. CML, pentosidine (↓)
2. Integrin, collagen, procollagen (↓)
Pageon and Asselineau, 2005 [98]
A reconstructed skin modelCEL, CML, MG-H1, or pentosidine1. Epidermal integrin α6 (↑)
2. Laminin-5 (↓)
3. Procollagen type I (↑)
4. MCP-1 (↑)
5. IL-6, MMP-1, MMP-3, vascular endothelial growth factor (VEGF) (↓)
Pageon et al., 2015 [99]
Reconstructed skin modelRibose (10 mM)1. Diameter of collagen lattice (↑)
2. Epidermal thickness (↑)
3. Dermal thickness (↓)
4. Dermal collagen aggregation (↑)
5. CML (↑)
6. Suprabasal integrin β1 (↑)
Blueberry extract, AGD1. Diameter of collagen lattice (↓)
2. Epidermal thickness (↓)
3. Dermal thickness (↑)
4. Dermal collagen aggregation (↓)
5. CML (↓)
6. Suprabasal integrin β1 (↓)
Pageon et al., 2008 [71]
Human dermal fibroblasts (HDFs)AGEs of BSA1. Senescence-associated β-galactosidase (SA-β-gal)-positive cells (↑)Fucose- or rhamnose-rich oligo- and polysaccharides1. SA-β-gal-positive cells (↓)Ravelojaona et al., 2009 [72]
HDFsAGEs of BSA1. MMP-2, MMP-9 (↑)Fucose- or rhamnose-rich oligosaccharides1. MMP-2, MMP-9 (↓)Robert et al., 2010 [100]
Reconstructed skin modelRibose (10 mM)1. Dermal thickness (↓)
2. CML (↑)
3. Collagen type VII, procollagen type III, glycosaminoglycans (↑)
4. MMP-2 (↑)
AGD1. Collagen type VII, procollagen type III, glycosaminoglycans (↓)
2. MMP-2 (↓)
Pageon et al., 2014 [74]
Reconstructed skin model (MimeskinTM)Ribose (0.5 M)Diameter of collagen fibers (↓)Davilla extract, AGDDiameter of collagen fibers (↑)Danoux et al., 2014 [75]
Dead human dermisUV irradiation1. Soluble fluorescent AGE levels (↑)
2. Soluble pentosidine-like AGE levels (↑)
3. Reactive oxygen species (ROS) production (↑)
Argania extract, AGD1. Soluble fluorescent AGE levels (↓)
2. Soluble pentosidine-like AGE levels (↓)
3. ROS production (↓)
HDFsAGEs of BSA (100 μg mL−1)1. ROS production (↑)
2. SA-β-gal-positive cells (↑)
Akebia quinata fruit extract1. ROS production (↓)
2. SA-β-gal-positive cells (↓)
Shin et al., 2015 [77]
Endothelialized and innervated reconstructed skin modelGlyoxal (200–500 μM)1. Increased CML (↑)
2. Number of capillaries (↓)
3. Platelet endothelial cell adhesion molecule (PECAM) 1, loricrin, filaggrin, and Krüppel-like factor (KLF) 4 (↓)
AGD, alagebrium (ALT-711)1. Increased CML (↓)
2. Number of capillaries (↑)
3. PECAM-1, loricrin, filaggrin, and KLF-4 (↑)
Cadau et al., 2015 [101]
Reconstructed skin modelSodium glyoxylate1. Dermal thickness (↓)
2. CML expression (↑)
3. Cytokeratin (CK) 10 and CK-14 (↑)
4. E-cadherin and desmoglein (↑)
5. Gaps in the dermis (↑)
6. Collagen flattening/compression (↑)
AGD1. Dermal thickness (↑)
2. CML expression (↓)
3. CK-10 and CK-14 proteins and mRNAs (↓)
Pennacchi et al., 2015 [78]
HDFs UVB radiation with glyceraldehyde-induced AGEs of BSA (100 μg mL−1)1. ROS production (↑)
2. RAGE protein (↑)
3. MMP-1 protein (↑)
4. TNF-α, IL-1β, and IL-6 (↑)
5. Phosphorylation of extracellular signal-regulated kinase (ERK), p38 mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase (JNK) (↑)
6. Nuclear factor (NF)-κB/p65 subunit nuclear translocation and inhibitor of NF-κB (IκBα) phosphorylation (↑)
Plantamajoside1. ROS production (↓)
2. RAGE protein (↓)
3. MMP-1 protein (↓)
4. TNF-α, IL-1β, and IL-6 (↓)
5. Phosphorylation of ERK, p38-MAPK, and JNK (↓)
6. IκBα phosphorylation and p65 nuclear translocation (↓)
Han et al., 2016 [79]
HaCaT keratinocytes
HaCaT keratinocytesGlyoxal (5 mM)1. Cell viability (↓)
2. Fluorescent AGE levels (↑)
3. Free fatty acids (↑)
Yokota and Tokudome, 2016 [97]
Reconstructed skin modelGlyoxal (2.5–10 mM)1. Free fatty acids (↑)
2. TEWL (↑)
Dead mouse skinGlyoxal 50 mM1. Skin color yellowness (↑)
2. TEWL (↑)
HDFsMethylglyoxal-modified collagen1. Cell viability (↓)
2. Apoptosis (↑)
3. Endoplasmic reticulum stress (↑)
4. Oxidative stress (↑)
N-Acetylcysteine1. Apoptosis (↓)
2. Oxidative stress (↓)
Nowotny et al., 2018 [50]
Reconstructed skin modelRibose (10 mM)1. Epidermal thickness (↑)
2. Collagen aggregates (↑)
3. Fibril and filament (↑)
4. Integrin β1, laminin-5, loricrin (↑)
5. Filaggrin (↓)
Balansin Rigon et al., 2018 [102]
Reconstructed skin modelRibose (10 mM), glucose (200 mM)1. Dermis thickness (↓)Alkaloids from Ocoteaparanapiacabensis, AGD1. Dermis thickness (↑)Freitas et al., 2020 [85]
HaCaT keratinocytes, human foreskin fibroblasts, THP-1 cellst-Butylhydroperoxide1. SA-β-gal-positive cells (↑)
2. IL-6, IL-8, MMP-1, MMP-3 (↑)
Carnosine1. CD36, RAGE in macrophages derived from THP-1 cells (↑)
2. Protein kinase B (AKT) 2 phosphorylation (↑)
3. Macrophage-mediated elimination of senescent skin cells (↑).
Li et al., 2020 [103]
Hs68 cellsMethylglyoxal (400 μM)1. Cell viability (↓)
2. ROS generation (↑)
Pholiota nameko polysaccharides1. Cell viability (↑)
2. ROS generation (↓)
Lin et al., 2021 [88]
HL-60 cellsAGEs of BSA (0.5 μg mL−1)1. Neutrophil migration and cluster formation (↓) Kang et al., 2021 [52]
HDFsUVB radiation1. Pentosidine, AGEs, methylglyoxal (↑)
2. Denatured collagen (↑)
3. MMPs 1, 3, and 9 (↑)
Hydrolyzed fish collagen (25% tripeptide)1. Pentosidine, AGEs, methylglyoxal (↓)
2. Denatured collagen (↓)
3. Collagen expression (↑)
4. MMPs 1, 3, and 9 (↓)
Lee et al., 2022 [104]
RAW264.7 cellsMethylglyoxal (100–400 μM)1. Cell viability (↓)Vanillic acid1. Cell viability (↑)Alhadid et al., 2022 [92]
HDFsGlucose-induced AGEs (0.5 mM)1. MMP-1 mRNA (↑)Cirsium japonicum flower extract1. MMP-1 mRNA (↓)Yoon et al., 2022 [90]
Hs68 CellsCML (100 μg mL−1)1. ROS production (↑)
2. RAGE protein (↑)
3. Collagen contents (↓)
Djulis (Chenopodium formosanum) extract1. ROS generation (↓)
2. RAGE protein (↓)
3. Collagen contents (↑)
Lyu et al., 2022 [105]
HaCaT keratinocytesUVA radiation1. AGE levels (↑)Sunflower sprout extract1. AGE levels (↓)Barua et al., 2022 [106]
Fibroblasts in collagen gelsGlyoxal (400, 1000 μM)1. Contraction of collagen gel (↓)
2. Fluorescent AGE levels (↑)
3. CML-protein (↑)
4. CMA-protein (↑)
5. RAGE protein (↑)
6. IL-8 mRNA (↑)
Chlorella (Parachlorella beijerinckii) extract, AGD1. Contraction of collagen gel (↑)
2. Fluorescent AGE levels (↓)
3. CML-protein (↓)
4. CMA-protein (↑)
5. RAGE protein (↓)
6. IL-8 mRNA (↓)
Imai et al., 2022 [91]
HDFsMethylglyoxal (500 μM)1. Autofluorescence (AGEs) (↑)
2. Cell density and proliferation (↓)
3. ROS production (↑)
Carnosine, resveratrol, oxyresveratrol, piceatannol1. Autofluorescence (AGEs) (↑)
2. Cell density and proliferation (↓)
3. ROS production (↑)
Markiewicz et al., 2022 [107]
Full-thickness skin model (EpiDermFT)1. Skin model diameter (↓)
2. Autofluorescence (AGEs) (↑)
3. CML (↑)
4. Eosin fluorescence (↓)
5. Epidermal thickness (↓)
6. Cell density and proliferation (↓)
7. Collagen density (↓)
1. Autofluorescence (AGEs) (↓)
2. CML (↓)
3. Eosin fluorescence (↑)
4. Epidermal thickness (↑)
5. Cell density and proliferation (↑)
6. Collagen density (↑)
HDFs (formaldehyde-fixed)Glyoxal (0.5%)1. AGE levels (↑)Jasminum sambac cell extract1. AGE levels (↓)Ceccacci et al., 2022 [108]
Macrophages derived from THP-1 cellsMethylglyoxal-modified BSA (300 μg mL−1)1. Cell viability (↓)
2. ROS production (↑)
3. TNF-α and IL-1β (↑)
Hazelnut (Corylus avellana) skin extract (rich in polyphenols)1. Cell viability (↑)
2. ROS production (↓)
3. TNF-α and IL-1β (↓)
Spagnuolo et al., 2023 [94]
HDFsMethylglyoxal (400 μM)1. Cell viability (↓)
2. SA-β-gal-positive cells (↑)
3. Collagen type I alpha 1 chain (COL1A1) (↓)
4. AKT, JNK, p38-MAPK, c-Jun, and NF-κB phosphorylation (↑)
5. MMP-1 (↑)
Carica papaya fruit extract, AGD1. Cell viability (↑)
2. SA-β-gal-positive cells (↓)
3. COL1A1 (↑)
4. AKT, JNK, p38-MAPK, c-Jun, and NF-κB phosphorylation (↓)
5. MMP-1 (↓)
Wattanapitayakul et al., 2023 [109]
Fibroblasts in collagen gelsGlyoxal (600 μM)1. Contraction of collagen gel (↓)N-Acetylhydroxyproline1. Contraction of collagen gel (↑)Knoblich et al., 2024 [95]
HDFsMethylglyoxal (500 μM)1. AGE levels (↑)
2. RAGE protein (↑)
Supramolecular carnosine1. AGE levels (↓)
2. RAGE protein (↓)
Bai et al., 2024 [110]
HDFsH2O2 (25 μM)1. SA-β-gal-positive cells (↑)
2. Superoxide dismutase (SOD), catalase (CAT) activity (↓)
3. p-NF-κB/NF-κB ratio (↑)
4. IL-1β, IL-6 (↑)
5. MMP-1, MMP-9 (↑)
6. AGE levels (↑)
K formulation (containing hyaluronan, collagen type I peptide)1. SOD, CAT activity (↑)
2. Nuclear factor erythroid 2-related factor (NRF) 2 expression (↑)
3. p-NF-κB/NF-κB ratio (↓)
4. IL-1β, IL-6 (↓)
5. MMP-1, MMP-9 (↓)
6. AGE levels (↓)
Augello et al., 2024 [111]
HDFs, human epidermal keratinocytes (HEKs), HaCaT keratinocytesGlyoxal-modified BSA (100 μg mL−1), UVB radiation1. Cell viability (↓)
2. Nitric oxide and ROS production (↑)
3. TNF-α, IL-1β, IL-6, IL-8 (↑)
4. NF-κB/p65 phosphorylation
5. RAGE and cyclooxygenase (COX) 2 (↑)
6. COL1A and NAD-dependent deacetylase sirtuin-1 (SIRT1) (↓)
Sultana et al., 2024 [96]
Table 5. Effects of glycation and various interventions on the pathological responses of skin explants ex vivo. Upward (↑) and downward (↓) arrows indicate increases and decreases, respectively.
Table 5. Effects of glycation and various interventions on the pathological responses of skin explants ex vivo. Upward (↑) and downward (↓) arrows indicate increases and decreases, respectively.
ModelGlycation InducersInduced ChangesInterventionsOutcomesReferences
Human skin explantsMethylglyoxal (500 μM)1. Fibrillin-1 protein (↓)
2. CML expression (↑)
Silybum marianum flower extract, AGD1. Fibrillin-1 protein (↑)
2. CML expression (↓)
Shin et al., 2015 [76]
Human skin explantsMethylglyoxal (500 μM)1. Fibrillin-1 protein (↓)
2. CML expression (↑)
Akebia quinata fruit extract, AGD1. Fibrillin-1 protein (↑)
2. CML expression (↓)
Shin et al., 2015 [77]
Human skin explantsMethylglyoxal (500 μM)1. Pentosidine expression (↑)
2. CML expression (↑)
Carnosine1. Pentosidine expression (↓)
2. CML expression (↓)
Narda et al., 2018 [113]
Human skin explantsMethylglyoxal (500 μM)1. Fibrillin-1 protein (↓)
2. CML expression (↑)
Methyl gallate1. Fibrillin-1 protein (↑)
2. CML expression (↓)
Shin et al., 2022 [89]
Human skin explantsMethylglyoxal (500 μM)1. CML expression (↑)Dunaliella salina extract1. RAGE (↓)
2. IL-6 and IL-8 (↓)
3. NRF2 (↑)
Havas et al., 2022 [114]
Human skin explantsMethylglyoxal (500 μM)1. Fibrillin-1 protein (↓)Jasminum sambac cell extract, AGD1. Fibrillin-1 protein (↑)Ceccacci et al., 2022 [108]
Human breast skin explantsGlycolaldehyde (25 mM)1. Autofluorescence (↑)Fructosamine 3-kinase, fructosyl-amino acid oxidase1. Autofluorescence (↓)De Decker et al., 2023 [115]
Hypertrophic scar tissue explants Fructosamine 3-kinase1. Elongation rate (↑)
Skin explantsGlucose (1 M)1. Autofluorescence (↑)N-Acetylhydroxyproline1. Autofluorescence (↓)Knoblich et al., 2024 [95]
Table 6. Effects of glycation and various interventions on the pathological responses of the skin in experimental animals in vivo. Upward (↑) and downward (↓) arrows indicate increases and decreases, respectively.
Table 6. Effects of glycation and various interventions on the pathological responses of the skin in experimental animals in vivo. Upward (↑) and downward (↓) arrows indicate increases and decreases, respectively.
ModelGlycation InducersInduced ChangesInterventionsOutcomesReferences
Wistar ratsStreptozotocin (50 mg kg−1, i.p.)1. Blood glucose (↑)
2. Glycosylated Hb (↑)
3. Skin collagen fluorescence (↑)
Rutin (1 g L−1) or AGD (1 g L−1) in drinking water 1. Skin collagen fluorescence (↓)Odetti et al., 1990 [117]
Emory mice prone to age-related cataractAge (6.5–22 months)1. Plasma glucose (↑)
2. Tail tendon breakdown time (↑)
3. Dermatological lesions (↑)
Restricted diet with different compositions (high protein and low carbohydrates)1. Lifespan (↑)
2. Cataract grade (↓)
3. Plasma glucose (↓)
4. Glycohemoglobin (↓)
5. Tail tendon breakdown time (↓)
6. Dermatological lesions (↓)
Taylor et al., 1995 [118]
Brown-Norway ratsAge (4–25 months)1. CML and pentosidine in skin collagen (↑)Caloric restriction1. CML, pentosidine, and fluorescence in collagen (↓)Cefalu et al., 1995 [26]
Fischer 344 rats, Age (6–24 months) 1. Furosine and pentosidine in skin collagen (↑)Diet restriction1. Furosine and pentosidine in skin collagen (↓)Sell, 1997 [119]
C57BL/6NNia miceAge (1–26 months)
Sprague–Dawley ratsAge (2–24 months)1. Skin and aortic collagen-linked fluorescence (↑)
2. Glycated plasma protein and Hb (↓)
Diet restriction1. Glycated plasma proteins and fluorescent products in skin collagen of younger rats (↓)
2. Did not affect glycated Hb or aortic collagen fluorescence.
Novelli et al., 1998 [120]
BALB/c miceGlucose (10% in feed)1. Blood glucose (-)
2. Fluorescent AGE levels in dorsal subcutaneous tissues (↑)
3. Calibers of arterial microvessels (↓)
4. Vascular lesion indices (↑)
AGD (0.25%) in drinking water1. Calibers of arterial microvessels (↑)
2. Vascular lesion indices (↓)
Yamada and Ohkubo, 1999 [121]
Broiler breeder chicksAge (8–92 weeks)1. Skin pentosidine (↑)Diet restriction (60% of control) and AGD (400 ppm) in feed1. Skin pentosidine (↓)Iqbal et al., 1999 [122]
C57 BL/6J miceGalactose (50 mg kg−1, s.c.) 1. Serum AGE levels (↑)
2. Motor activity (↓)
3. Memory latency time (↓)
4. Memory error (↑)
5. Lymphocyte proliferation (↓)
6. IL-2 production (↓)
AGD (0.1%) in drinking water1. Serum AGE levels (↑)
2. Motor activity (↑)
3. Memory latency time (↑)
4. Memory error (↓)
5. Lymphocyte proliferation (↑)
6. IL-2 production (↑)
Song et al., 1999 [123]
Fischer 344 ratsAge (3–26 months), diets with different carbohydrate sources1. The source of dietary carbohydrates (cornstarch, sucrose, glucose, fructose, or a combination of glucose and fructose) had little effect on serum glycemic stress and AGE levels Diet restriction1. Serum glucose and glycated Hb (↓)
2. Pentosidine in the collagen of a tail tendon (not skin or trachea) (↓)
Lingelbach et al., 2000 [124]
Broiler breeder chicksAllopurinol (10 mg kg−1, p.o.) or hemin (10 mg kg−1, p.o.)1. Skin pentosidine (↑)Diet restriction1. Skin pentosidine (↓)Klandorf et al., 2001 [125]
Fisher 334 ratsAge (6–24 months)1. Plasma glucose (↑)
2. Tail tendon breakdown time (↑)
3. Glycation (furosine) and glycoxidation (pentosidine and CML) of skin collagen (↑)
AGD (1 g L−1) in drinking water1. There were no effects except for marginal effects on tail tendon breakdown time Sell et al., 2001 [126]
C57BL/6 miceAge (1, 4, 8–10.5 months)1. Skin furosine and pentosidine (↑)
2. Tail collagen fluorescence (↑)
3. Tail tendon breakdown time (↑)
Vitamins C and E, blueberry, and green tea extracts1. (Green tea extract) tail collagen fluorescence (↓)
2. (Green tea extract) tail tendon breakdown time (↓)
Rutter et al., 2003 [127]
Sprague–Dawley ratsStreptozotocin (45 mg kg−1)1. Crosslinking of skin collagen (↑)
2. Acid solubility of tail collagen (↓)
N-phenacylthiazolium and N-phenylacy-4,5-dimethylthiazolium halides, pyridoxamine1. There were no effectsYang et al., 2003 [37]
Lewis ratsStreptozotocin (65 mg kg−1, i.v.)1. Red blood cell-immunoglobulin (Ig) G crosslink (↑)
2. Tail tendon collagen crosslink (↑)
ALT-711 (10 mg kg−1, oral)1. Red blood cell-IgG crosslink (↓)
2. Tail tendon collagen crosslink (↓)
Vasan et al., 2003 [36]
Fischer 344 ratsAged 24 months ALT-711 (5%, topical)1. Skin elasticity (↑)
2. Skin hydration (↑)
Squirrel and rhesus monkeysAge1. Rate of furosine formation in skin collagen (↑?)
2. Rate of pentosidine formation in skin collagen (↑?)
3. No change for CML
Diet restriction (70% of control)1. Rate of furosine formation in skin collagen of rhesus monkeys (↓)
2. No change in pentosidine or CML level
Sell et al., 2003 [128]
Nude miceGalactose (1000 mg kg−1, s.c.)1. Serum AGE levels (↑)
2. Skin SOD activity (↓)
3. Skin MDA level (↑)
4. Dermal thickness (↓)
5. Skin collagen (↓)
6. Skin CD31-positive vessels density (↓)
7. Skin VEGF expression (↓)
Adipose-derived stem cells (1 × 106 per injection)1. Serum AGE levels (↓)
2. Skin SOD activity (↑)
3. Skin MDA level (↓)
4. Dermal thickness ↑)
5. Skin collagen (↑)
6. Skin CD31-positive vessels density (↑)
7. Skin VEGF expression (↑)
Zhang et al., 2014 [129], Wang et al., 2016 [130]
CormorantsAge (1–5 years)1. Hydroxyproline (↑)
2. Pentosidine (↑)
Dorr et al., 2017 [131]
ICR miceGalactose (120 mg kg−1, i.p.)1. Skin AGE levels (↑)
2. Skin collagen type I, III (↓)
3. Skin hyaluronan (↓)
4. Skin H2O2 (↑)
Lactobacillus fermentum CQPC04-fermented soy milk (10 mL kg−1)1. Skin AGE levels (↓)
2. Skin collagen type I, III (↑)
3. Skin hyaluronan (↑)
4. Skin H2O2 (↓)
Zhou et al., 2021 [132]
DBA/2CrSlc miceUV radiation1. Ear skin Cu/Zn-SOD expression and total SOD activity (↓)
2. Ear skin CAT expression and activity (↓)
Mycosporine-like amino acid-containing emulsions (0.25 μmol g−1) (50 mg per ear, topical)1. Skin Cu/Zn-SOD expression and total SOD activity (↑)
2. Skin CAT expression and activity (↑)
3. No changes in AGE levels of ear skin
Waditee-Sirisattha and Kageyama, 2021 [87]
Sprague–Dawley ratsStreptozotocin (35 mg kg−1, i.p.)1. Serum fructosamine and HbA1c (↑)
2. AGE levels in the kidneys and tail skin (↑)
Vanillic acid (1.5, 4.5, or 15 mg kg−1, i.p.)1. AGE levels in the kidneys and tail skin (↓)Alhadid et al., 2022 [92]
HR-1 miceUVB radiation1. Wrinkle area, length, and depth (↑)
2. Skin and epidermal thickness (↑)
3. Skin moisture (↓)
4. Skin collagen and hyaluronan (↓)
5. Skin levels of AGEs and RAGE (↑)
Schizonepeta tenuifolia extract (containing rosmarinic acid)1. Wrinkle area, length, and depth (↓)
2. Skin and epidermal thickness (↓)
3. Skin moisture (↑)
4. Skin collagen and hyaluronan (↑)
5. Skin levels of AGEs and RAGE (↓)
Gu et al., 2023 [133]
C57BL/6 miceUV radiation1. Skin melanin (↑)
2. Skin ROS (↑)
3. Skin AGE levels (↑)
Idebenone-loaded nanoparticles1. Skin melanin (↓)
2. Skin ROS (↓)
3. Skin AGE levels (↓)
Xie et al., 2023 [134]
Hairless miceStreptozotocin (45 mg kg−1, i.p.)1. Skin wrinkle index (↑)
2. Skin hydration (↓)
3. Skin elasticity (↓)
4. Blood and skin levels of AGEs, CML, RAGE (↑)
5. Skin collagen and hyaluronan (↓)
6. Skin MMP-9 (↑)
7. Skin SOD and CAT activity (↓)
8. Skin TNF-α, IL-6 (↑)
Goji berry, fig, and Korean mint extracts)1. Skin wrinkle index (↓)
2. Skin hydration (↑)
3. Skin elasticity (↑)
4. Blood and skin levels of AGEs and skin CML (↓)
5. Skin collagen (↑)
6. Skin IL-6 (↓)
Yoo et al., 2023 [135]
Swiss albino miceGalactose
(500 mg kg−1, i.g.)
1. Skin TNF-α, IL-1β, and malondialdehyde (MDA) (↑)
2. Skin glutathione peroxidase (GPX) (↓)
3. Skin collagen type I, III (↓)
Dapagliflozin (1 mg kg−1)1. TNF-α, IL-1β, and MDA (↓)
2. Skin GPX (↑)
3. Skin collagen type I, III (↑)
Shihab et al., 2024 [136]
Table 7. Clinical studies on the effects of various interventions on the glycation levels and skin aging parameters in human subjects.
Table 7. Clinical studies on the effects of various interventions on the glycation levels and skin aging parameters in human subjects.
Study Format or SizeTest MaterialsTreatmentsOutcomesReferences
A randomized, placebo-controlled study involving 22 subjects with type 2 diabetesA dietary supplement containing 400 mg of vitamin E and 500 mg of vitamin CThe oral supplement was taken daily for a year.1. Neither the treatment nor placebo group had significant changes in AGE level.Konen et al., 2000 [137]
A double-blinded, placebo-controlled trial involving 40 womenA cream containing 10% green tea extract, an oral supplement (300 mg) containing green tea extractThe cream was applied to the face and arms, and the oral supplement was taken twice a day for 8 weeks.1. No significant effects on the scoring of skin parameters by a physician and patients.
2. Histologically improved elastic tissue content of treated specimens.
Chiu et al., 2005 [138]
A single-center study enrolling 20 women with type II diabetes aged >50 A topical product formulation containing blueberry extract and C-xylosideSubjects used the product on their face, hands, and inner forearms twice daily for 12 weeks. 1. Increased skin thickness and hydration.
2. Improved fine lines, firmness, radiance, skin tone, smoothness, creping, and overall appearance.
Draelos et al., 2009 [139]
A randomized, double-blinded, controlled study involving 42 subjectsA capsule containing carnosine, N-acetylcysteine, histidine, vitamin E, pantethine, methionine, and zinc picolinateThe capsule was taken orally every second day for 3 months, followed by a 1-month supplementation-free period.1. Improved skin appearance, fine lines, and shiny look.
2. Improved the skin surface parameters, contrast, and circular roughness.
Babizhayev et al., 2012 [140]
21 adult volunteersA cream containing 3% Argania plant extract, α-tocopheryl acetate, rutin, and ferulic acidThe cream was applied to the skin for 2 weeks.1. Decreased the UVA-induced chemiluminescence of the skin, a measure of free radical production.Danoux et al., 2014 [75]
A single-center, randomized controlled trial on 57 post-menopausal womenAn equol supplement containing 98% S-equol, 2% daidzein, 0.2% glycitein, and 0.1% genisteinThe supplement (10 mg) was taken orally for 3 months.1. Improved climactic symptoms without effects on metabolic or aging-related biomarkers, including AGEs.
2. In certain populations (internal equol producers supplemented with external equol), AGE levels and visceral fat area were reduced.
Yoshikata et al., 2021 [141]
Twenty-two healthy womenAn ampule containing hydrolyzed fish collagen (25% tripeptide) The ampule was applied to the entire face twice daily for 4 weeks.1. Improved periorbital and glabellar skin wrinkles, skin surface elasticity, and dermal density.
2. Reduced skin AGE levels.
Lee et al., 2022 [104]
A randomized, double-blinded, split-face, placebo-controlled trial on 25 female volunteersA gel cream containing Dunaliella salina extract (rich in colorless carotenoids, such as phytoene and phytofluene)One side of the face received the active product, and the other received the placebo for 56 days.1. Reduced skin AGE levels.
2. Reduced histamine-stimulated microcircular blood flow.
3. Reduced periocular wrinkles and red spots.
Havas et al., 2022 [114]
Female subjects aged from 50 to 65A lotion containing 0.025% Cirsium japonicum flower extractTopically applied to the face twice a day for 8 weeks.1. Decreased depth and volume of wrinkles.
2. Reduced maximum depth of the biggest wrinkle but not the total wrinkle area.
3. Increased skin elasticity.
Yoon et al., 2022 [90]
A double-blinded, randomized, controlled, single-center case study on 28 female subjects.A serum containing sunflower sprout extractThe product was applied alone or in combination with a moisturizer lotion twice daily for 7 days.1. Improved facial conditions, such as radiance, smoothness (tactile), fine lines of crow’s feet, and overall eye appearance.Barua et al., 2022 [106]
A randomized, double-blinded, placebo-controlled trial on 31 individualsFish-derived collagen peptides (rich in prolyl-hydroxyproline and hydroxyprolyl-glycine)Ingested collagen peptide (5 g) or placebo (maltodextrin) daily for 12 weeks.1. Improved skin AGE levels and insulin resistance index (homeostasis model assessment ratio).Koizumi et al., 2023 [142]
A split-face, placebo-controlled study involving 32 volunteersAn essence containing 0.5%, 1%, or 2% supramolecular carnosineTopically applied to the face for 28 days.1. Reduced brown spots.
2. Increased lightness (L* value) and individual topology angle (ITAo) and decreased melanin index of the facial skin.
Bai et al., 2024 [110]
Single-blinded clinical trials with 9 and 34 participantsA serum that claims to be anti-agingTopically applied to the face for 7 or 56 days.1. Reduced skin AGE levels.
2. Improved skin brightness and hydration, but not skin texture (elasticity, firmness).
Zhang et al., 2025 [143]
A randomized, double-blinded, placebo-controlled trial on 104 female participantsA capsule containing 300 mg of rosemary extract, 2 μg of biotin, and 0.45 mg of zinc gluconate Subjects were instructed to take two capsules three times daily for weeks 1 to 4, two times daily for weeks 5 to 8, and one capsule two times daily for weeks 9 to 12.1. Decreased the levels of 4-hydroxynonenal-protein adducts in the skin compared to both baseline values and the placebo group at 12 weeks.
2. Reduced skin AGE levels compared to both baseline values and placebo controls at 12 weeks.
Guiotto et al., 2025 [144]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Choi, J.Y.; Ha, N.G.; Lee, W.J.; Boo, Y.C. Synthetic and Natural Agents Targeting Advanced Glycation End-Products for Skin Anti-Aging: A Comprehensive Review of Experimental and Clinical Studies. Antioxidants 2025, 14, 498. https://doi.org/10.3390/antiox14040498

AMA Style

Choi JY, Ha NG, Lee WJ, Boo YC. Synthetic and Natural Agents Targeting Advanced Glycation End-Products for Skin Anti-Aging: A Comprehensive Review of Experimental and Clinical Studies. Antioxidants. 2025; 14(4):498. https://doi.org/10.3390/antiox14040498

Chicago/Turabian Style

Choi, Joon Yong, Nam Gyoung Ha, Weon Ju Lee, and Yong Chool Boo. 2025. "Synthetic and Natural Agents Targeting Advanced Glycation End-Products for Skin Anti-Aging: A Comprehensive Review of Experimental and Clinical Studies" Antioxidants 14, no. 4: 498. https://doi.org/10.3390/antiox14040498

APA Style

Choi, J. Y., Ha, N. G., Lee, W. J., & Boo, Y. C. (2025). Synthetic and Natural Agents Targeting Advanced Glycation End-Products for Skin Anti-Aging: A Comprehensive Review of Experimental and Clinical Studies. Antioxidants, 14(4), 498. https://doi.org/10.3390/antiox14040498

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop